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Human pharmacology of tranquilizing drugs 
The widespread confusion in the classification of various tranquilizing drugs is due to the 
fact that there are no specific tranquilizers at this time. All available drugs ~ave numerous 
pharmacologic actions in addition to ataraxia. Some of the newer drugs used to relieve 
anxiety are related pharmacologically to the well-known classic sedative and soporific 
compounds. Some agents, like chlorpromazine and reserpine, etc., have much less 
soporific effect but do have other marked pharmacologic actions. The position of the reviewer 
is that there are no truly specific tranquilizers and that most central nervous system 
depressants in proper dose or circumstance may be used clinically in man to relieve anxiety 
and produce tranquilization. The concept of the dose-response relationship of these agents 
is discussed. Drugs with relatively flat dose-response curves for central nervous system 
depression tend to be the most useful in relieving anxiety without producing too many 
undesirable actions. 
The pharmacology of several selected agents and related congeners is discussed in 
detail. These include the substituted phenothiazines, the Rauwolfia alkaloids, meprobamate, 
and chlordiazepoxide. 
Edward F. Domino, M.D. Ann Arbor, Mich. 
Department of Pharmacology, University of Michigan 
It is easy to define a tranquilizer as a 
substance which relieves anxiety and pro-
duces calmness, peacefulness, serenity, 
placidity, or ataraxia. It is not easy, how-
ever, to select specific pharmacologic 
agents to include in a rational classification 
of tranquilizers. Numerous central nervous 
system depressants, some stimulants, and a 
few drugs with no central effects whatso-
ever may in proper dose and circumstance 
relieve anxiety and produce tranquilization. 
Few physicians would object to the classi-
fication of reserpine, chlorpromazine, and 
their related congeners as tranquilizing 
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agents. There would be considerable dis-
agreement, particularly among psychiatrists 
and pharmacologists, as to the preCise cate-
gorization of ethyl alcohol, barbiturates, 
meprobamate, hydroxyzine, benactyzine, 
chlordiazepoxide, and other nonbarbiturate 
sedatives. 
It is usually assumed that tranquilizers 
induce psychologic and physiologic states 
qualitatively different from sedative-sopo-
rific drugs. Few would disagree with the 
marked differences in pharmacology be-
tween chlorpromazine and the barbiturates, 
but many would disagree with claims made 
that meprobamate is pharmacologically 
uniquely different from some barbiturates 
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or ethyl alcohol. Inasmuch as there are in-
adequate data on the uniqueness of the 
psychologic states induced by these agents, 
it is readily understandable why disagree-
ment and confusion are Widespread. This 
is reflected and propounded by the myriad 
of advertisements referring to numerous 
heterogeneous drugs as calmative, eunoic, 
relaxant, neurosedative, psychosedative, or 
even more imaginative terms.278 
Numerous classifications of tranquilizing 
drugs have been suggested. Berger28 pro-
posed a classification based in part on 
chemical structure and in part on the pres-
ence or absence of autonomic nervous 
system-blocking properties. Reserpine, the 
substituted phenothiazines, and related 
compounds were considered central au-
tonomic suppressants. On the other hand, 
propanediols such as meprobamate and 
various diphenylmethane derivatives were 
classified as tranquilizers without auto-
nomic-blocking properties. Such a proposal 
did little to define the place of barbiturates. 
Pfeiffer and colleagues248 provided evidence 
that meprobamate has some pharmacologic 
properties similar to barbiturates, including 
the production of "barbiturate-like" fast 
waves in the electroencephalogram of man. 
Are other sedative drugs to be classified 
along with meprobamate as tranquilizers 
without autonomic-blocking properties? 
Ross and Cole268 proposed a classification 
based on psychiatric usage in which agents 
were classified as major or minor tranquiliz-
ing drugs. Schiele and Benson273 have sug-
gested a similar classification. They defined 
major tranquilizing drugs as those charac-
terized by ( 1) production of emotional 
calmness and mental relaxation, (2) high 
effectiveness in controlling the symptoms of 
acutely and chronically disturbed psychotic 
patients, (3) production in susceptible pa-
tients of reversible extrapyramidal symp-
toms, and (4) little to no tendency to pro-
duce phYSical dependence or habituation. 
These agents are drugs of choice in excited, 
delusional, and psychotic states. The minor 
tranquilizing drugs were characterized as 
agents which produced calmness and re-
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laxation but not of the same "quality" as 
the major tranquilizers. Precisely what was 
meant by this was difficult to define. The 
authors suggested that such agents are par-
ticularly useful in common psychoneurotic 
problems but are not very effective in 
treatment of severely disturbed psychotic 
patients. These agents do not produce ex-
trapyramidal symptoms and have a rela-
tively low incidence of annoying effects, 
except that physical dependence does occur 
to some. The minor tranquilizers are pre-
ferred in common nervous states such as 
nervous tension, mild depression, psycho-
somatic disorders, etc. 
Seevers278 has suggested that because of 
the marked heterogeneity of pharmacologiC 
substances called tranquilizers and because 
knowledge of the primary sites of actions 
of these compounds is extremely limited, 
the term tranquilizer be abandoned as hav-
ing any specific pharmacologic meaning. 
He proposed that such drugs be classified 
on the basis of their predominant pharma-
cologic actions in man based upon whether 
the agents produced nonselective or selec-
tive depression of the central nervous sys-
tem. There is ample evidence that Seevers 
is fundamentally correct in his aversion to 
"tranquilizer" as having no specific phar-
macologic connotation. Friend,103 in his 
review of tranquilizers, includes reserpine 
and its derivatives, phenothiazines, pro-
panediols, diphenylmethanes, barbiturates, 
and a host of nonbarbiturate sedatives. In 
the same publication, Pelikan and Kens-
ler244 review these agents as sedatives. The 
latter have reviewed the problem of de-
fining sedation. They suggest that clinically 
the sedative properties of reserpine and 
chlorpromazine seem qualitatively differ-
ent from those of the barbiturates and 
other related compounds. Certainly, animal 
as well as human toxicity data would sup-
port the notion that deep coma or anesthe-
sia is usually not seen after large doses of 
reserpine and chlorpromazine as compared 
to the barbiturates. Electroencephalo-
graphiC and behavioral arousal may occur 
with increased afferent input in both ani-
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mals and man after large doses of reserpine 
and chlorpromazine but not after large 
doses of barbiturates. Evidence in animals 
and man on the sites of action of these and 
other central nervous system depressants 
clearly indicates that there are remarkable 
qualitative differences.83 Nevertheless, it is 
of considerable interest that Klerman and 
colleagues173 could not distinguish between 
the qualitative effects of three psychoactive 
drugs given in therapeutic doses to normal 
human subjects. These investigators com-
pared on a double blind basis two dose 
levels of meprobamate (as a tranquilizer), 
phenyltoloxamine (as a sedative-antihis-
taminic ), and secobarbital (as a sedative-
hypnotic) and a placebo given in Single 
oral doses. The effects of these agents were 
observed on (1) various physiologic func-
tions including heart rate, respiration, 
blood pressure, skin temperature, muscle 
tension, and pupil size, (2) level of con-
sciousness and alertness as determined by 
rating scores, (3) psychomotor perform-
ance as measured by tapping speed and 
pursuit rotor coordination, ( 4) mental 
functioning as measured by serial addition 
and a learning task, (5) subjective activity, 
and (6) behavior during a psychiatric in-
terview. The data obtained indicated that 
the three psychopharmacologic drugs used 
had somewhat similar effects. On the basis 
of these results as well as those obtained 
from a previous study with phenyltolox-
amine and reserpine,79 Klerman and col-
leagues concluded that the special prop-
erties of "tranquilizing" drugs do not lie 
in their ability to induce psychologic states 
uniquely different from sedation. Rather, 
the critical feature was related to the dose 
margins between sedative effects and those 
affecting psychomotor performance and 
consciousness. Thus, they considered seda-
tion and tranquilization as similar psycho-
logic states. Clinically, an important differ-
ence between a tranquilizer and a sedative 
is the greater degree of soporific effect pro-
duced by the latter. 
From a pharmacologic point of view, the 
list of agents used clinically as tranquilizers 
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includes drugs with many diverse actions. 
Numerous agents have been found em-
pirically in man to reduce the intensity of 
hyperemotional states such as anxiety. At 
the present time, there are no drugs which 
have only this specific property. To date, 
drugs which depress anxiety have numer-
ous other actions in the body. For example, 
narcotics such as morphine are effective in 
relieving anxiety but have marked addic-
tion liability which prevents their wide-
spread use as tranquilizers. Many of the 
sedative-hypnotics such as phenobarbital 
likewise reduce anxiety but may in larger 
dosage cause marked drowsiness. The 
newer tranquilizing drugs are said to have 
fewer adverse effects but do in fact have 
many diverse pharmacologic actions. At 
the present time, there are no specific tran-
quilizing drugs. 
Perhaps what determines whether a seda-
tive drug is used clinically to produce tran-
quilization is the slope of its dose-response 
curve for central nervous system depres-
sion. A drug with a shallow dose-response 
curve probably will be a useful tranquiliz-
ing agent because there will be a greater 
spread between the dose producing weak 
sedation (or tranquilization) and the dose 
producing a soporific effect. Although qual-
itative differences exist between sedative-
hypnotics (like barbiturates) and some 
tranquilizers (like reserpine and chlorprom-
azine ), one must be aware that in proper 
dose and circumstance, a variety of central 
nervous system depressants may produce 
the clinical phenomenon of tranquilization. 
It is, therefore, my view that most central 
nervous system depressants can be classi-
fied as tranquiliZing drugs. 
The following classification is proposed 
of some central nervous system depressants 
which in proper dose or circumstance may 
produce tranquilization: 
1. Drugs with primarily sedative-soporific effects 
A. Bromides 
B. Alcohols 
1. Ethanol 
2. Chloral hydrate 
3. Petrichloral 
602 Domino 
C. Aldehydes 
1. Paraldehyde 
D. Acetylenic carbinols and derivatives 
1. Methylparafynol 
2. Ethchlorvynol 
3. Ethinamate 
E. Urea derivatives 
1. Monoureids 
a. Carbromal 
b. Bromisovalum 
c. Ectylurea 
2. Diureids 
a. Barbiturates 
F. Piperidinediones 
1. Methyprylon 
2. Glutethimide 
G. Drugs of miscellaneous chemical struc-
ture with alleged skeletal muscle relaxant, 
analgesic, or other 'more selective central 
actions 
1. Meprobamate 
2. Promoxolane 
3. Phenaglycodol 
4. Chlormethazanone 
5. Carisoprodol 
6. Chlordiazepoxide 
7. Phenyramidol 
8. Mephenoxalone 
9. Mebutamate 
10. Hydroxyphenamate 
II. Narcotic analgesics, including morphine and 
similar agents 
III. Drugs with predominantly antihistaminic 
effects 
1. Diphenhydramine 
2. Hydroxyzine 
3. Promethazine 
4. Phenyltoloxamine 
5. Chlorphenoxamine 
IV. Drugs with predominantly catecholamine and 
serotonin depleting effects 
A. Rauwolfia alkaloids 
1. Reserpine 
2. Alseroxylon 
3. Deserpidine 
4. Rescinnamine 
5. Syrosingopine 
B. Synthetic agents 
1. Tetrabenazine 
2. a-Methyl DOPA 
V. Substituted phenothiazines with predominantly 
catecholamine and serotonin blocking effects 
1. Promazine 
2. Chlorpromazine 
3. Thioridazine 
4. Mepazine 
5. Proclorperazine 
6. Perphenazine 
7. Thiopropazate 
8. Triflupromazine 
9. Trifluoperazine 
10. Fluphenazine 
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VI. Drugs with predominantly cholinergic block-
ing effects 
A. Some Solanaceae alkaloids such as sco-
polamine 
B. Benactyzine 
Drugs such as ethyl alcohol or the bar-
biturates produce various degrees of cen-
tral nervous system depression, depending 
upon dose. Relatively small doses of these 
agents produce a mild depression of the 
central nervous system which may be con-
sidered weak sedation or tranquilization in 
man. With pentobarbital, this might occur 
with oral doses of perhaps 50 mg. Doses of 
pentobarbital in the order of 100 to 200 
mg. may produce a definite sedative-so-
porific or drowsy state in which sleep de-
velops depending upon environmental cir-
cumstances. Doses of pentobarbital 5 to 10 
times as large may produce a state of semi-
coma or coma. Thus, the range of dosage 
between mild sedation, a soporific effect, 
semicoma, and coma is in the order of two-
fold to tenfold. What distinguishes reser-
pine and chlorpromazine from the barbi-
turates (in addition to certain qualitative 
differences) is that the range of dosage be-
tween mild sedation and coma is extremely 
large. In man, a dose of chlorpromazine 
of 50 to 100 mg. may produce mild seda-
tion. A tenfold increase in dosage generally 
produces only a more definite sedative ef-
fect. Coma can seldom be produced with 
the phenothiazines. Patients who ingest 
several grams of these agents may appear 
in a semicomatose state with marked hypo-
tension, but even in this state, marked af-
ferent stimuli transiently arouse the pa-
tient. This is even more true of reserpine 
and its derivatives. Compounds such as 
meprobamate resemble ethyl alcohol and 
the barbiturates more than the phenothia-
zines or reserpine. Meprobamate has an 
intermediate range of doses between those 
producing mild sedation, a soporific effect, 
and coma. This wider range of dosage per-
haps contributes to its popularity as a tran-
quilizing drug. Obviously, marked qualita-
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tive differences do exist in the pharmacol-
ogy of many drugs used clinically to pro-
duce tranquilization. Nevertheless, it is 
suggested that any central nervous system 
depressant which produces weak sedation 
in doses smaller than those which produce 
drowsiness potentially is a clinically use-
ful tranquilizing agent. 
There has been a great deal of research 
on the pharmacology of tranquilizing 
agents in animals, normal human subjects, 
and psychiatric patients. In fact, the world-
wide literature is so enormous that it is not 
possible to be even reasonably complete. 
This review is an attempt to correlate the 
author's knowledge of animal pharmacol-
ogy with that in man of a relatively small 
number of tranquilizing agents, based upon 
a cursory literature survey. In discussing 
the pharmacologic actions of certain drugs, 
it was frequently necessary to refer to data 
in animals which are not available in man. 
Whenever appropriate, some studies in 
which the therapeutic actions of a given 
compound were compared with one or 
more standard control agents have also 
been included in this review. 
Substituted phenothiazines 
Although the phenothiazines have been 
known for many decades, their use in hu-
man medicine was limited until the past 
15 years. Historically, phenothiazine itself 
was employed as a urinary antiseptic and 
anthelmintic. Toxicity precluded its wide-
spread use. Introduction of promethazine 
in 1945 as an antihistaminic with sedative 
properties prompted further synthesis of 
other derivatives of phenothiazine. This 
was culminated in 1950 by the successful 
synthesis of chlorpromazine by Charpen-
tier. Since then, numerous substituted 
phenothiazines have found a place in clin-
ical medicine. 
Structure-activity relationships. Some of 
the structure-activity relationships of these 
compounds were reviewed by Friend104 in 
the Current Drug Therapy section of this 
journal. Several new compounds have since 
appeared. 
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The substituted phenothiazines may be 
classified on the basis of chemical struc-
ture.'" 
A. Compounds with a propyl dimethyl-
amino subgroup 
Promazine 
(~/S'-() ~/J"'N/ ~ CH3 
I / 
CH,CHCH,N 
I '" CH3 CHs 
Trimeprazine 
CXS:O-OCH' 
N CH, 
I / 
CH,CHCH,-N 
I '" CH3 CH3 
Methotrimeprazine 
()/S"'O ~ I~ /1 ~-OCH, 
N CH, 
I / 
CH,CH,CH2N 
'" CH, 
Methoxypromazine 
~Formulas will usually be drawn as the base in this 
article. 
604 Domino 
Chlorpromazine 
()/S'''--O ~ I~/"I #-CF3 
N CH, 
I / 
CH,CH2CH2N 
"-CHa 
Triflupromazine 
B. Compounds with a propyl piperazine 
subgroup 
Proclorperazine 
()/S~O ~ I "--~ /" I # -SCH,CH3 
N 
I 1\. 
CH,CH2CH2-N N-CH3 
~ 
Thiethylperazine 
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Thioperazine 
Acetophenazine 
Carphenazine 
Perphenazine 
(XSD_CJ 
N ~ 0 
I / \ II CH2CH2CH'-N~N_CH,CH'OCCH' 
Trifluoperazine Thiopropazate 
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CXS:O-CH' 
~ 1\ CH,CH2CH2N~N-CH2CH20H 
Fluphenazine 
C. Compound with a methyl piperidyl 
subgroup 
Mepazine 
D. Compound with an ethyl piperidyl 
subgroup 
Thioridazine 
E. Compound with a propyl piperidyl 
subgroup 
Pipamazine 
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F. Compound with a methyl pyrrolidyl 
subgroup 
Methdilazine 
C. Compounds with an ethyl dimethyl-
amino subgroup 
o:~nJ 
I /CH, 
CH,CH-N 
I "-CH3 CH3 
Chlorpromethazine 
~ I 0 O/s~o ~ 1'),/ J J CII,CII, 
I /CH3 
CH,CHN 
I "-CH3 CH, 
Propiomazine 
s 
CXN:O 
I /CH3 
CH,CHN 
I "-CH, CH:, 
Promethazine 
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H. Compounds with an ethyl diethyl-
amino subgroup 
Diethazine 
(Xs:C) 
N I /CH,CH3 
CH2CHN 
I '" CH3 CH2CH3 
E thopropazine 
1. Compound with an ethyl pyrrolidyl 
subgroup 
o=~:o 
I! 
CH2CH2N~ 
Pyrathiazine 
The substituted phenothiazines have a 
very complex pharmacology and have ef-
fects at many different sites in the body. 
They act in the central nervous system, 
producing (1) sedation, (2) block of con-
ditioned avoidance behavior, ( 3 ) anti-
emetic effects, (4) alteration of temperature 
regulation, (5) alteration of skeletal mus-
cle tone, (6) antipruritic effects, (7) anal-
gesic effects, ( 8 ) facilitation of seizure 
discharge, and (9) endocrine changes. 
They act in the autonomic nervous sys-
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tern, producing (1) cholinergic blocking ef-
fects at nicotinic and muscarinic receptor 
sites, (2) adrenergic blocking effects (alpha 
type), (3) adrenergic potentiating effects 
(especially norepinephrine), (4) antihista-
minic effects, and (5) antiserotonin effects. 
They potentiate the action of various 
drugs. 
Finally, they induce local anesthesia. 
The substituted phenothiazines differ 
quantitatively and qualitatively in the ex-
tent of each of these pharmacologic effects. 
They also vary in the degree of untoward 
effects, including agranulocytosis, photo-
sensitivity, extrapyramidal symptoms, jaun-
dice, and pigmentary retinopathy. It is not 
easy to make valid generalizations with re-
gard to their structure-activity relation-
ships.ll7 A few principles do emerge which 
may facilitate retention of some of the 
known facts about the phenothiazines. 
Generally, compounds which contain the 
I I / 
-C-C-N side chain in position 10 with 
I I "'-
two carbons between the nitrogens have 
increased antihistaminic properties ( pro-
methazine and pyrathiazine). Compounds 
I I I / 
with a -C-C-C-N side chain in posi-
I I I "'-
tion 10 with three carbons between the 
two nitrogens have increased effects in 
blocking conditioned avoidance behavior 
as well as increased adrenergic blocking 
properties. Substitution of CI for a hydro-
gen in position 2 of the phenothiazine ring 
for compounds with three carbons between 
the two nitrogens usually increases po-
tency for depressing conditioned avoidance 
behavior (chlorpromazine versus proma-
zine). On the other hand, a 2-CI substitu-
tion in compounds with two carbons be-
tween the two nitrogens reduces potency 
for depressing conditioned avoidance be-
havior ( 2-chlorpromethazine versus pro-
methazine). An OCR] group in position 2 
is almost as effective as a CI substitution 
( methoxypromazine versus chlorproma-
zine). The CF3 substitution in position 2 
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produces a marked increase in potency 
(triflupromazine, trifluorperazine, and flu-
phenazine ). Other position 2 substitutions 
which also increase potency include 
o CH 1 
II / 
-S-N 
II '" o CH" 
o 
II ( thioperazine) and -C-CH" 
( acetophenazine ). The 2-thio-substituted 
compounds appear to produce fewer un-
toward extrapyramidal effects ( thiorida-
zine and thiethylperazine versus proclor-
perazine ). 
Substitution of a piperazine group in 
place of the terminal dimethylamino moiety 
increases potency for central effects, in-
cluding extrapyramidal symptoms, for ex-
ample, proclorperazine versus chlorpro-
mazine. A further increase in potency is 
obtained by replacing a CI with a CF, 
group (proclorperazine versus trifluopera-
zine). Substitution of -CH2CH20H for 
the terminal CH" group on piperazine also 
results in a slight increase in potency (per-
phenazine versus proclorperazine) . Even 
greater central potency, including extra-
pyramidal symptoms, is obtained by sub-
stituing CF 3 for CI (fluphenazine versus 
perphenazine). Quaternization of the ter-
minal nitrogen of chlorpromazine de-
creases lipid solubility, reducing penetra-
tion through the blood-brain barrier. This 
results in a compound with markedly di-
minished central nervous system effects. 
The tissue distribution of certain quater-
nized phenothiazines is markedly altered, 
with much less appearing in brain than in 
the case of their tertiary analogues. 7 , 32, 125 
Some agents with a terminal N-diethyl 
group possess interesting antiparkinsonian 
effects and increased nicotinic cholinergic 
blocking properties (diethazine and etho-
propazine). Both drugs also possess anti-
histaminic properties. Phenothiazines used 
especially for their antihistaminic proper-
ties include promethazine and pyrathiazine. 
Clinically useful antipruritic effects have 
been ascribed especially to trimeprazine 
and methdilazine. These latter agents ap-
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pear to be less effective tranquilizers. Most 
of the substituted phenothiazines with 
three carbons between the terminal nitro-
gens also possess marked antiemetic effects. 
In small doses, they depress the chemore-
ceptor trigger zone, but in larger doses, 
they have a direct depressant effect on the 
vomiting center.111 Thiethylperazine has 
been claimed to be effective in depressing 
both of these medullary vomiting areas, but 
further data are necessary to evaluate its 
usefulness and specificity. Although chlor-
promazine and promethazine are not clin-
ically effective analgesic agents, Lasagna 
and De Kornfeld194 have data on a new 
phenothiazine, methotrimeprazine, indicat-
ing that milligram for milligram in doses 
of 10 to 15 mg. subcutaneously given to 
bedridden postoperative and postpartum 
patients, it was as effective as morphine. 
However, doses of 25 mg. of methotri-
meprazine given orally to ambulatory pa-
tients produced untoward effects such as 
dizziness, fainting, drowsiness, and vomit-
ing (also seen in 1 patient with a placebo) 
but no analgesia superior to a placebo. 
Sedation and postural hypotension occur 
with this phenothiazine. They suggest that 
this and other phenothiazines be studied 
further for analgesic properties. 
The ramifications of the structure-activ-
ity relationship of the phenothiazines ap-
pear to be limited only by available dis-
crete screening tests and chemical imagina-
tion. The rather stereotyped structure-ac-
tivity relationship of compounds clinically 
available attests probably to the lack of 
suitable animal screening tests for unique 
therapeutically desirable properties in man. 
As such screening procedures are devel-
oped, one can probably anticipate many 
more interesting phenothiazine analogues. 
It would appear that the numerous phar-
macologic effects of the substituted pheno-
thiazines can be partially separated by ap-
propriate "molecule manipulation." This is 
in sharp contrast to the multipliCity of 
other drugs with which milligram potency 
and duration of action are the primary 
pharmacologic variables altered by minor 
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Ol/-"C~ ~ "---./ ~ C 
I /CH, 
CH2CH,CH,N 
'" CR, Imipramine 
O:SD 
0:0 
o 
II /CR: 
CHCH,CH2N 
'" 
CH, 
Amitriptyline 
N 
I 
CH, 
Cyproheptadine N N 
I 
CH3 
/ 
CH,CH,CH,N 
'" 
CH, 
Prothipendyl 
chemical substitutions, for example, the 
numerous thiazide diuretics. The appear-
ance of newer compounds related to the 
phenothiazines is ample evidence of the 
fruitfulness of the grab bag attempts in 
molecular manipulation. The appearance 
of imipramine and amitriptyline as psychic 
energizers is the direct result of minor al-
terations in the structure of promazine. 
These agents (especially imipramine) ap-
pear to have a more marked norepineph-
rine-potentiating action than the parent 
phenothiazine. Other alterations of the 
phenothiazine ring may result in com-
pounds with primarily sedative effects, as 
in the case of prothipendyl, which is also 
modeled after promazine, and chlorpro-
thixene, which is modeled after chlorprom-
azine. Cyproheptadine is another ana-
logue with serotonin-blocking and hista-
mine-blocking properties of value as an 
antipruritic. 
The choice of a phenothiazine to use as 
a tranquilizing agent depends upon the 
type of patient, the potency, and possible 
untoward effects of the drug. In usual 
therapeutic doses, frequently, it matters 
little which of the many phenothiazines 
Chlorprothixene 
/ 
with a -CH2CH2CH2 N substitution are 
'" 
used. For example, Hollister, Caffey, and 
Kletp43 compared the complications in 
schizophrenic patients after 12 weeks of 
treatment with chlorpromazine, triHuprom-
azine, mepazine, proclorperazine, per-
phenazine, and phenobarbital. Many ab-
normal symptoms and signs which were 
thought to be associated with phenothia-
zine therapy also occurred with phenobar-
bital. For example, leukopenia was not 
significantly more frequent from the phe-
nothiazines than from phenobarbital! 
Changes in body temperature, pulse rate, 
and blood pressure were uncommon, with 
no significant differences in frequency of 
occurrence among various drugs used. Ob-
viously, this lack of undesirable effects is 
in part related to the dosage used. 
Behavioral effects. The administration of 
chlorpromazine and other phenothiazines 
to man produces depreSSion of the central 
nervous system. The subject may become 
sleepy, but arousal to various afferent stim-
uli usually occurs easily. After chlorproma-
zine, psychotic patients appear less severely 
disturbed. Generally, this antipsychotic ef-
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fect is more likely to be seen on chronic 
administration than acutely. Acute drug 
administration does, however, produce a 
quieting effect in grossly agitated and dis-
turbed patients. Recently, Tuteur, Stiller, 
and Glotzer311 reviewed the results of chlor-
promazine administration over a 5 year 
period to once denudative, incontinent, 
combative, destructive psychotic female 
patients with lengthy hospitalizations. At 
the end of the 5 year period in which 913 
patients were treated, 273 were discharged. 
Of the latter, 75 returned to the hospital; 
28 relapsed while taking chlorpromazine 
diligently. Extensive controls were not 
available. Nevertheless, it would appear 
that chlorpromazine has antipsychotic ef-
fects in some patients. Because of hospital 
discharges, the original treatment area of 
814 beds could be decreased by removing 
154 beds permanently. Somewhat similar 
results were described by Kris '89 in a 5 
year follow-up study involving patients 
given a variety of pharmacologic agents, 
predominantly phenothiazines. 
It is a common clinical impression that 
the sedative or antipsychotic effects of the 
substituted phenothiazines are qualitatively 
different from those of other central ner-
vous system depressants such as the barbi-
turates. There is good evidence to support 
this widespread impression. The sites and 
mechanisms of action of chlorpromazine 
are certainly uniquely different from those 
of the barbiturates. s3 An interesting experi-
ment which illustrates the differences in 
pharmacology of chlorpromazine and phe-
nobarbital was reported by Lasagna and 
McCann'95 with mice. The toxicity of am-
phetamine is much less for isolated than 
for aggregated mice. In single isolated 
mice, neither phenobarbital nor chlorprom-
azine in the doses used had an appre-
ciable effect on the LD50 of amphetamine. 
In grouped animals, however, chlorprom-
azine gave significant protection against 
amphetamine, while phenobarbital did not 
unless anesthetic doses were used. Further 
evidence of the differences between chlor-
promazine and a barbiturate on objective 
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behavioral tests has been provided by 
Brady, Nurnberger, and Tausig.39 These 
investigators attempted an experimental 
analysis of some young adult psychotic pa-
tients using operant conditioning tech-
niques now widely used to analyze animal 
behavior. In a preliminary study the de-
tails of which unfortunately were not pre-
sented, they compared the effects of single 
oral doses of chlorpromaZine and secobar-
bital given to psychotic subjects who de-
veloped a stable operant behavioral pat-
tern. Chlorpromazine affected the fixed in-
terval mean delays and the tendency for 
delays in most subjects in the same direc-
tion as clinical improvement had occurred 
over a long period of treatment. Secobar-
bital had no such effect. 
Clinical studies on the comparative ef-
ficacy of the substituted phenothiazines 
and barbiturates also support the notion of 
a unique antipsychotiC effect of the phe-
nothiazines. For example, Casey and co-
workers,57 in an extensive double blind 
study involving various cooperating veter-
ans administration hospitals, reported on 
the therapeutic effectiveness of phenothia-
zines in contrast to phenobarbital and a 
placebo in 692 schizophrenic men. Twelve 
week periods were used for the drug treat-
ments. Chlorpromazine (400 mg. daily) 
was more effective than promazine (400 
mg. daily), while phenobarbital (200 mg. 
daily) and placebo (lactose) were rela-
tively ineffective. When phenothiazine 
medication followed the control medica-
tions (phenobarbital or lactose), clinical 
improvement increased. When the con-
trol medication was given after the pheno-
thiazines, however, the gains obtained after 
the phenothiazines perSisted for the addi-
tional 12 week period of the study. This 
may be related to the fact that phenothia-
zine metabolites may still be present for 
this length of time after stopping medica-
tion (see section on metabolic fate). The 
results of this study, furthermore, support 
the clinical impression that antipsychotic 
effects of phenothiazines are unrelated to 
drowsiness to which tolerance develops. 
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Generally, chlorpromazine is not con-
sidered a soporific agent, although Cutler, 
Monroe, and Anderson,67 reported that 150 
mg. of chlorpromazine administered three 
times a day to schizophrenics produces 
somnolence. Kornetsky, Yates, and Kes-
sler186 compared the effects of 100 and 200 
mg. of chlorpromazine, 200 mg. of chlor-
promazine and 200 mg. of secobarbital, 
and a placebo given orally to normal sub-
jects before bedtime. Both drugs produced 
a significant increase in sleeping time. Of 
considerable interest is that both drugs also 
significantly impaired the subjects' per-
formance on various psychologic tests the 
following morning, 14 to 15 hours after 
medication. This would indicate a possible 
hangover effect to both agents. Kornetsky 
and co-workers185 have noted that there is 
tolerance development to the effects of 
chlorpromazine (100 and 200 mg. twice a 
day for 11 days) on some behavioral tests 
after chronic administration to schizo-
phrenic patients. On the other hand, 
chronic administration of secobarbital (200 
mg.) still significantly reduced the level of 
performance. Single doses of 100 and 200 
mg. of chlorpromazine caused less impair-
ment in schizophrenics than in normal sub-
jects. In contrast, single doses of secobar-
bital caused a similar degree of impairment 
of performance in schizophrenics and nor-
mal subjects. Kornetsky184 has summarized 
many of his previously reported studies, 
pointing out in particular the differences in 
the effects of chlorpromazine compared to 
other psychoactive drugs depending upon 
whether the drugs are given chronically or 
acutely. Furthermore, individual differ-
ences may affect the behavioral actions of 
the drugs. He has proposed the hypothesis 
(and offered some data in support) that 
the responder to one drug is also a respon-
der to other drugs. This also applies to 
drugs producing opposite effects. Kornetsky 
showed that human subjects impaired the 
most by chlorpromazine tended to be stim-
ulated the most by D-amphetamine. Al-
though not great (-0.48), the correlation 
coefficient was statistically significant. 
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Further evidence of tolerance develop-
ment to the sedative effects of chlorproma-
zine has been provided by Rosner, Ameen, 
and Kolers.267 These investigators com-
pared the effects of chronic administration 
of chlorpromazine, mephobarbital, and a 
placebo on tests of alertness in 11 acutely 
schizophrenic patients. A crossover design 
was used with drugs alternating after 6 
weeks. The subjects received 100 mg. of 
chlorpromazine four times a day and 200 
mg. of mephobarbital four times a day. 
After chronic administration of both drugs, 
there was no deficit of pedormance on 
various tests of alertness. This is to be 
contrasted with the results reported by 
Primac, Mirsky, and Rosvold,258 that Single 
dose administration of chlorpromaZine does 
adversely affect the performance of normal 
subjects on a "continuous pedormance 
test" of alertness. Interestingly, secobarbital 
did not have a deleterious effect. Similar 
effects were reported subsequently by 
Mirsky, Primac, and Bates.227 
Chlorpromazine usually markedly re-
duces motor activity in man and animals. 
Pathologic motor activity in psychotic pa-
tients is Significantly reduced by 600 mg. 
of chlorpromazine daily in contrast to a 
placebo in severely disturbed patients.67 
It is of interest that the drug also signifi-
cantly increased somnolence although this 
did not appear to be great enough to ac-
count for the decrease in pathologic activ-
ity. In view of the fact that there is evi-
dence for tolerance development to the 
sedative effects of chlorpromazine but not 
to the antipsychotic effects, it is of interest 
to note that in rats, Irwin 154 has observed 
tolerance to develop to the depression of 
conditioned avoidance by chlorpromazine 
or perphenazine within 2 weeks after 
chronic daily administration. No tolerance 
developed to the depression of locomotor 
activity. Irwin suggested on this basis that 
locomotor depressant effects in rats COrre-
lated better with antipsychotic activity 
than depression of conditioned avoidance. 
On acute administration, the two phenom-
ena were highly correlated in a series of 
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eight substituted phenothiazines, with the 
exception of promazine.155 The latter had a 
greater depressant effect on locomotor ac-
tivity than on conditioned avoidance. 
Cook and Weidley determined the spe-
cificity of chlorpromazine in blocking in-
strumental conditioned avoidance in rats. 
The conditioned avoidance response was 
selectively blocked by chlorpromazine, re-
serpine, and morphine, in contrast to the 
effects of barbital and methylparafynol. 
Pentobarbital and meprobamate affected 
the conditioned response in doses produc-
ing neurologic symptoms. Hertz135 re-
viewed much of the literature on the ef-
fects of a wide variety of psychopharma-
cologic agents on conditioned avoidance in 
animals. The available literature further 
supports the notion that chlorpromazine, 
reserpine, and morphine produce more 
selective depressant effects on avoidance 
than on escape behavior. Winsor333 re-
ported that in man, various phenothiazines, 
including chlorpromazine, proclorperazine, 
methoxyphenothiazine, and mepazine, pre-
vented the development of/or blocked con-
ditioned vasoconstriction in the fingers but 
not the unconditioned response to an elec-
tric shock. Pentobarbital and a placebo 
had no effect on the development or in-
hibition of conditioned vascular responses. 
No doses or descriptions of subjects, how-
ever, were included in this report. 
Ader and Clink2 determined the effects 
of chlorpromazine on the acquisition and 
extinction of a conditioned-avoidance shut-
tle box type of response in rats. Chlor-
promazine treatment increased the number 
of trials required to attain a given crite-
rion of learning and decreased the resist-
ance to extinction. The role of motor re-
tardation rather than a specific effect of 
chlorpromazine on acquisition or extinc-
tion was not determined. Schneider and 
Costiloe275 studied in man the effects of 
chlorpromazine, amobarbital, and pheni-
dylate on the spontaneous recovery and 
extinction of the galvanic skin response to 
a previously conditioned stimulus using 
electric shock as the unconditioned stim-
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ulus. Chlorpromazine inhibited recondi-
tioning, while phenidylate facilitated it. 
Amobarbital inhibited spontaneous recov-
ery and also tended to inhibit recondition-
ing. Truax308 was able to show that in 
contrast to placebo, 40 mg. of chlorproma-
zine facilitated the rate of eyelid condi-
tioning in human volunteers. During 
extinction, neither the drug nor placebo 
caused decrement per se, but the change 
from either produced block of the emo-
tionally conditioned response. A related 
study by the same investigator and asso-
ciates285 compared the effects of chlorprom-
azine ( 30 mg.) and a placebo given 
orally on motion studies of gait, manual 
performance in handwriting, object manip-
ulation, and panel control operations. Each 
of 40 human subjects acted as their own 
controls. Chlorpromazine was shown to 
Significantly increase the duration of fine 
manipulative movements after learning 
progressed, without affecting travel move-
ments or manipulative movements early in 
learning. The drug appeared to interfere 
or reduce the efficiency of fine motor con-
trol. Traugott and Balnov307 determined 
the effects of chlorpromazine on condi-
tioned and unconditioned reflexes as well 
as reaction and association responses in 
various patients. Chlorpromazine impaired 
conditioned activity and lessened simple, 
unconditioned reflexes. They also claimed 
their patients appeared less tense, more 
accessible, and better oriented after the 
drug. Alexander5, 6 also determined the ef-
fects on various drugs in man using the 
classic Pavlovian method of pairing a tone 
with an electric shock. He recorded the 
galvanic skin response. Chlorpromazine 
and related phenothiazines depressed the 
conditioned as well as the unconditioned 
responses. 
A few studies have been made on the 
objective behavioral effects in man of vari-
ous other phenothiazines. Benjamin, Ikai, 
and Clare25 determined the effects of 10 
mg. of proclorperazine and 10 mg. of phe-
nobarbital given orally to human volun-
teers on various psychologic, psychomotor, 
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and muscular performance tests. The re-
sults obtained were compared to those with 
a control group receiving no drug. Tests of 
hearing, pain perception, and mental per-
formance showed no specific drug-induced 
changes. Tests involving muscular coor-
dination, however, showed a decrease in 
performance as did tests of muscular exer-
cise. The amplitude of the patellar reflex 
was decreased by proclorperazine, whereas 
phenobarbital had no effect. Proclorpera-
zine Significantly prolonged the combined 
simple and choice reaction times and de-
pressed pursuit rotor performance more 
than phenobarbital. Wilson and Huby331 
compared the effects of thiopropazate (20 
mg. ), secobarbital (120 mg. ), caffeine (300 
mg.), and a lactose placebo in normal stu-
dents using subjective and objective ques-
tionnaires. The subjects were acquainted 
with the pharmacologic actions of the 
drugs and were asked to guess which agent 
they received. When the subjects guessed 
correctly, the drug effects were more 
marked than when they guessed incor-
rectly. It was felt that this was evidence 
that the pharmacologic actions of the drugs 
could be modified by anticipation of their 
effects. Thiopropazate could not be dis-
tinguished from secobarbital. Caffeine was 
preferred; it tended to cause wakefulness 
but was preceded by a period of drowsi-
ness. 
Klerman and DiMascio172 compared the 
effects of single doses of chlorpromazine, 
promethazine, perphenazine, and trifluo-
perazine in 36 normal human subjects using 
a double blind deSign. Various psychologic 
tests were used: alertness, psychomotor 
speed, steadiness, intellectual tasks, and 
mood. These were administered before and 
2, 4, and 7 hours after drug ingestion. Of 
considerable importance was the observa-
tion that the ethyl and propyl dimethyla-
mine derivatives (promethazine and chlor-
promazine) produced a marked decrease 
in psychomotor function, impairment of in-
tellectual tasks, and drowsiness. On the 
other hand, the propyl piperazine deriva-
tives (perphenazine and trifluoperazine) 
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had the opposite effects and elevated mood. 
A more detailed report of essentially the 
same study was given by DiMascio, 
Havens, and Snell. 78 ChlorpromaZine and 
promethazine (25, 50, 100 or 200 mg. per 
day) and perphenazine and tripfluopera-
zine (2, 4, 8, or 16 mg. per day) were all 
given orally. Chlorpromazine and prometh-
azine produced psychomotor inhibition, 
mental confusion, alterations in autonomic 
function, and sedation. In contrast, per-
phenazine and trifluoperazine resulted in 
minimal changes in all of these measures. 
At the highest dose levels of these two 
drugs, the subjects actively tried to go to 
sleep in order to eliminate some of the in-
ner stimulation they noted. In contrast, 
after chlorpromazine and promethazine, 
the subjects reported that sleep seemed to 
be forced on them. Chlorpromazine and 
promethazine produced pupillary constric-
tion, while perphenazine and trifluopera-
zine caused dilatation. When impairment 
of performance was noted with any of the 
drugs, there tended to be associated pupil-
lary constriction. Chlorpromazine was the 
only drug which tended to alter blood 
pressure. The authors suggested that many 
of the effects observed were perhaps more 
related to the untoward effects of the phe-
nothiazines than to their therapeutic or 
antipsychotic actions. 
Effects on the human electroencephalo-
gram. Numerous electroencephalographic 
studies have been published on the sub-
stituted phenothiazines. For purposes of 
brevity, only a few will be referred to in 
this review. Dobkin, Gilbert, and Lamou-
reux81 showed that after intravenous ad-
ministration of 0.3 to 2 mg. per kilogram of 
chlorpromazine to unanesthetized patients 
and volunteers, the electroencephalogram 
resembled that of light drowsiness. The 
subject could be easily aroused. The elec-
troencephalographic picture of drowsiness 
was represented by irregular, 5 to 6 cycles 
per second, low voltage theta waves in the 
central midline or midvertex area. The K 
complex which occurs as part of the elec-
troencephalographic arousal response in 
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drowsiness or sleep was also found. Of 
pharmacologic interest, neostigmine, caf-
feine, amphetamine, and edrophonium did 
not antagonize these electroencephalo-
graphic changes. SzatmarP03 observed that 
50 mg. of chlorpromazine given intrave-
nously produced the following changes in 
the human electroencephalogram: (1) 
marked muscle relaxation and disappear-
ance of muscle artifact, (2) a decrease of 
1% cycles per second in the alpha fre-
quency and a 30 per cent increase in volt-
age, ( 3 ) an increase in temporal and 
parietal 5 to 6 cycles per second theta 
activity, (4) drowsiness or light sleep pat-
terns, and (5) in epileptics, increased sen-
sitivity to hyperventilation. The tendency 
for increased synchronization and normal-
ization of the electroencephalogram was 
taken as evidence that chlorpromazine had 
a very mild depressant action on the reticu-
lar activating system. Some of the animal 
evidence would indicate that chlorproma-
zine does indeed have a mild depressant 
effect on this system. Glotfelty and Wil-
son 112 compared the effects of chronic 
administration (greater than 4 days) of 
chlorpromazine, promazine, and meproba-
mate on the electroencephalographic 
arousal response in various psychiatric pa-
tients to several afferent stimuli including 
visual, auditory, tactile, and nociceptive 
stimuli. Doses of 200 to 400 mg. of chlor-
promazine or promazine and 1,600 mg. of 
meprobamate given orally daily for at least 
4 days had no effect on electroencephalo-
graphic arousal responses in man. When 
promazine was given intravenously in doses 
of 75 to 200 mg., however, electroencepha-
lographic arousal responses were reduced 
markedly in duration. These data might be 
interpreted to mean that chronic oral ad-
ministration leads to tolerance so that de-
pressant effects on electroencephalographic 
arousal were not observed. On the other 
hand, an acute intravenous dose of proma-
zine (and probably chlorpromazine) does 
depress electroencephalographic arousal in 
man. Interestingly, Himwich, Rinaldi, and 
Willis1:lS proposed from an electroencepha-
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lographic study of a limited series of 
phenothiazines in rabbits that those pheno-
thiazines which failed to block electroen-
cephalographic arousal to painful stimuli 
on acute administration were inferior to 
chlorpromazine in managing psychotic pa-
tients. Paul-David and Unna243 compared 
a series of substituted phenothiazines in a 
quantitative manner on electroencephalo-
graphic arousal of the cat elicited by stim-
ulation of the brain stem reticular forma-
tion. All drugs were given intravenously. 
The minimal effective doses to depress the 
electroencephalographic arousal response 
for the drugs were: chlorpromazine, 0.5 
mg. per kilogram; chlorpromazine sulfox-
ide, 5 mg. per kilogram; trifluoperazine, 
0.02 mg. per kilogram; perphenazine, 0.1 
mg. per kilogram; and triflupromazine, 0.05 
mg. per kilogram. Promazine and thiorida-
zinc were less effective, and prochlorpera-
zinc was as effective as chlorpromazine in 
depressing the electroencephalographic 
arousal response. 
Swain and Littera1"99 obtained electroen-
cephalographic recordings during a double 
blind study of the effects of chlorpro-
mazine given chronically before, during, 
and various periods after cessation of medi-
cation to senile, brain-damaged patients. 
Electroencephalographic abnormalities con-
sisting of slowing persisted in some pa-
tients for 3 months or longer after the 
medication was discontinued. In contrast, 
Jorgensen and Wulff"59 studied the electro-
encephalographic effects of chlorpromazine 
and its withdrawal in a younger group of 
nonorganic psychiatric patients. Electroen-
cephalographic changes disappeared 10 
days after chlorpromazine withdrawal. It 
would appear that senile, brain-damaged 
patients show residual chlorpromazine ef-
fects much longer than younger patients 
without organic brain disease. 
Fink has proposed that increased elec-
troencephalographic synchronization and 
a shift of frequencies to the delta range 
commonly are associated with tranquiliza-
tion induced in psychiatric patients by the 
phenothiazines (particularly chlorproma-
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zine and promazine) . He distinguishes 
these electroencephalographic effects with 
those produced by the barbiturates, which 
regularly induce an increase in fast activity 
and synchrony, and sympathomimetics 
such as amphetamine, which increase fast 
activity without increased synchrony. In 
contrast, desynchronization is prominent 
after diethazine, lysergic acid diethylamide, 
and benactyzine. 
Effects on skeletal motor systems. On 
acute administration, chlorpromazine de-
presses skeletal muscle tone. For example, 
Sheatz282 was able to show that chlorprom-
azine abolished extensor hypertonicity 
and hyperreHexia in four of five dogs with 
midcollicular brain stem transections. In 3 
human patients with irreversible brain 
damage showing decorticate hypertonicity, 
100 mg. of chlorpromazine intramuscularly 
caused marked skeletal muscle relaxation. 
Basmajian and Szatmari18, 19 were able 
to confirm the fact that chlorpromazine can 
reduce skeletal muscle spasticity in some 
patients with neurologic lesions. Patients 
showing spasticity caused by lesions of 
upper motor neurons were dramatically 
improved after chlorpromazine. Of con-
siderable theoretic interest was the fact 
that the drug reduced the tremor and rigid-
ity of parkinsonism for about 2 hours. 
These investigators postulated that the 
agent depressed bulbar facilitatory areas 
in the brain stem. Henatsch and Ingvar134 
showed in cats that chlorpromazine has a 
marked depressant effect, especially on 
central gamma motor systems. They sug-
gested that forms of spasticity and rigidity 
which are reduced by chlorpromazine are 
probably mediated over the gamma motor 
system. The depressant effect of chlorprom-
azine on skeletal muscle tone is appar-
ently due to an action on the brain stem. l5l 
Chlorpromazine has been reported to be 
effective in controlling the skeletal muscle 
spasms of tetanus in man.15, 198 
Laurence and Webster199 have observed, 
however, that after repeated doses of chlor-
promazine over an 8 hour period to rabbits 
with local tetanus, tolerance developed 
Clinical Pharmacology 
and Therapeutics 
rapidly. Subsequently, larger doses had no 
suppressant effect and usually facilitated 
the tetanus spasms. After the depressant 
effect of a large dose of chlorpromazine 
wore off, it was usually followed by en-
hanced activity. If a second dose was given 
during the next 24 hours, there was an im-
mediate activation of the response which 
could be abolished by a barbiturate or 
mephenesin. Levomepromazine was a more 
effective depressant than chlorpromazine. 
In a human case of tetanus, levomeproma-
zine gave symptomatic relief in a dose of 
25 mg. intravenously and 400 mg. daily on 
succeeding days. 
The effects of the phenothiazines on the 
extrapyramidal system are well known. 
Generally, these effects are considered to 
be incidental to the antipsychotic actions 
of the phenothiazines, although some have 
regarded the two to be related. This im-
pression is strengthened by the fact that 
the more potent antipsychotic agents show 
a greater tendency to produce extrapyrami-
dal symptoms. Goldman115 studied in 5,000 
state hospital patients the extrapyramidal 
syndromes induced by various drugs in-
cluding the phenothiazines, reserpine, and 
related compounds. There appeared to be 
no relationship between dosage, antipsy-
chotic effect, and induced parkinsonism. 
Phenothiazines with a position 10 propyl 
dimethylamino substitution and a position 
2 chlorine or triHuoromethyl group induced 
parkinsonian phenomena. Among the posi-
tion 10 propyl piperazine derivatives, extra-
pyramidal symptoms were induced by the 
sulfondimethylamide, triHuoromethyl, and 
chlorine substitutions in position 2. The 
neurologic effects of tetrabenazine and 
haloperidol outweighed their therapeutic 
effectiveness. Goldman felt that the appar-
ent correlation between the ability to in-
duce parkinsonism and to suppress psy-
chotic symptoms was highly misleading. 
Actions on cardiovascular system. The 
descriptions of Dobkin, Gilbert and Lam-
oureux81 on the pharmacologic effects of 
intravenous chlorpromazine (0.3 to 2 mg. 
per kilogram) to healthy human subjects 
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are classic. After chlorpromazine, the sub-
jects became drowsy, listless, pale, calm, 
and apathetic. Their skin was dry and 
warm. Horner's syndrome was present bi-
laterally. The subjects had a feeling of 
motor weakness and were chilly and 
thirsty. The axillary, oral, and rectal tem-
peratures decreased 2 to 4° F. At the same 
time, the temperatures in the extremities 
rose. Arterial blood pH and sodium, po-
tassium, chloride, and phosphate levels did 
not change, but the bicarbonate content 
fell. Arterial oxygen, carbon dioxide con-
tent, hematocrit, and hemoglobin deter-
minations showed no change. Arterial blood 
sugar rose, while blood urea nitrogen fell. 
The subjects showed orthostatic hypoten-
sion, and the heart rate rose slightly. The 
tidal volume was depressed, but the rate of 
respiration increased and was irregular. 
Doses of 1 to 2 mg. per kilogram of chlor-
promazine produced definite respiratory 
depression and in 1 subject dyspnea. The 
electroencephalogram showed a normal 
sleep pattern. The subjects were easily 
aroused by afferent stimuli and often 
showed a hyperactive response. After 
chlorpromazine, there was a marked de-
crease in gastric secretions, but insulin 
caused a marked response, indicating that 
the vagus was functional. In a small num-
ber of cases, the movements of athetosis 
and chorea were suppressed, nausea and 
vomiting were controlled, and chronic pro-
longed pain was controlled with chlorprom-
azine and smaller doses of meperidine. 
Foster and colleagues100 studied the effects 
of chlorpromazine given intravenously in 
doses of 5 to 25 mg. in conscious as well as 
anesthetized subjects. These doses caused 
varying degrees of tachycardia and pos-
tural hypotension. By means of plethys-
mography, they were able to show that 
chlorpromazine produced vasodilation in 
the hand, calf, and forearm on intravenous 
and intra-arterial injection. Blood flow was 
further increased in the hand after block 
of the brachial plexus by local anesthesia. 
Chlorpromazine reduced the hypertension 
induced by intravenous norepinephrine and 
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blocked the reflex bradycardia. Vasocon-
striction follOWing intra-arterial infusion of 
norepinephrine, however, was not reduced, 
but that to epinephrine was. Epinephrine 
reversal was not observed. It would appear 
that chlorpromazine in the doses used had 
a weak alpha adrenergic blocking action 
and a possible ganglionic blocking effect. 
Using larger doses in animals, numerous 
investigators have shown that chlorproma-
zine produces alpha adrenergic block. 
There are marked differences among the 
various phenothiazines in this regard. 89 The 
metabolic effects of epinephrine, however, 
are not blocked. Gupta, Patel, and Joseph122 
have shown that chlorpromazine alone pro-
duces significant hyperglycemia in the rab-
bit. A similar effect in man was observed 
by Dobkin, Gilbert, and Lamoureux. 81 Al-
though chlorpromazine blocked the pressor 
response, it did not block the hypergly-
cemic response to epinephrine. 
Moyer230 compared the animal and hu-
man pharmacology of chlorpromazine. In 
general, the pharmacologic effects are simi-
lar. In man, chlorpromazine reduced the 
blood pressure of normotensive as well as 
hypertenSive patients. Intravenous adminis-
tration produced more marked hypotension 
than via the intramuscular or oral route. 
The hypotension was much less marked in 
recumbent patients than when they were 
erect. Associated with the hypotension was 
a decrease in cerebral blood flow. Cerebral 
oxygen uptake is not affected by chlorprom-
azine inasmuch as the arteriovenous oxy-
gen difference increased during these in-
duced Circulatory changes. With doses of 
50 to 100 mg. intravenously, adrenergic 
block was incomplete. Norepinephrine 
pressor effects were reduced to about one-
half. On chronic administration, tolerance 
developed to the hypotensive effect of 
chlorpromazine so that even doses as large 
as 2 Gm. given orally did not lower blood 
pressure. In man, chlorpromazine, either 
acutely or chronically, does not appear to 
cause any consistent alteration of glomeru-
lar filtration rate, renal plasma flow, or 
electrolyte excretion patterns. This is in 
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contrast to some data in anesthetized dogs 
in which in large doses (3 to 5 mg.) of 
chlorpromazine may elicit a moderate diu-
retic response with an increase in sodium 
excretion. Ginsburg and Duffllo compared 
the effects of intra-arterial and intravenous 
epinephrine before and after intra-arterial 
and intravenous chlorpromazine on the 
hand blood flow of human volunteers. Be-
fore chlorpromazine, epinephrine caused a 
decrease of hand blood flow; after chlor-
promazine, the basal flow increased mark-
edly. Subsequently, epinephrine caused a 
much smaller decrease in hand blood flow. 
No reversal of epinephrine vasoconstriction 
of the hand was' found, no matter whether 
intra-arterial (1.2 mg.) or intravenous (50 
mg.) chlorpromazine was used. Chlorprom-
azine via both routes was more effective 
in antagonizing intra-arterial than intra-
venous epinephrine. The data on lack of 
epinephrine reversal are in agreement with 
the studies of Foster and colleagues/oo who 
also showed a reduction of peripheral epi-
nephrine vas constriction but inconclusive 
evidence of epinephrine reversal. Duff and 
Ginsburg87 subsequently did a similar study 
using intra-arterial and intravenous injec-
tions of norepinephrine and chlorpromazine 
on the hand blood flow of human volun-
teers. The infusion of chlorpromazine into 
the brachial artery caused a marked reduc-
tion of the vasoconstrictor response to nor-
epinephrine. The effect was attributed 
primarily to a direct vasodilator action but 
also to block of norepinephrine. In com-
paring these results with those previously 
obtained with epinephrine, these investiga-
tors pointed out that chlorpromazine ap-
pears to be more effective in reduCing the 
vasoconstriction of the blood vessels of the 
human hand by norepinephrine than epi-
nephrine. In fact, the reduction in the con-
strictor response to epinephrine could be 
wholly accounted for by the vasodilatation 
produced by chlorpromazine. In various 
laboratory animals, chlorpromazine may 
reduce or reverse the pressor effects of epi-
nephrine and reduce those of norepineph-
rine. 66 • ISO Rarely, an enhancement of the 
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norepinephrine blood pressure response has 
been observed, espeCially with small doses 
of chlorpromazine. 
The discrepancies between the animal 
and available human data probably can be 
accounted for more on the basis of differ-
ences in the vascular beds studied and 
anesthesia than of species differences. Lan-
zoni, Li, and Etstenl!n determined the cir-
culatory effects of 0.15, 0.25, and 0.35 mg. 
per kilogram of proclorperazine given in-
travenously to various patients. Within 2 
minutes after administration of proclor-
perazine, there was a 6 to 10 per cent fall 
in diastolic and systolic blood pressure and 
a 5 to 10 per cent increase in heart rate. 
These effects lasted only 10 to 15 minutes. 
A slight decrease (10 per cent) in the 
blood pressure rise to the Valsalva ma-
neuver was noted after proclorperazine. 
Endocrine effects. Numerous investiga-
tors have described the endocrine changes 
induced by the phenothiazines. The effects 
obtained depend upon the dose, duration 
of treatment, and species. In large doses, 
chlorpromazine and reserpine17 and per-
phenazineIG induce a pseudopregnancy 
response in animals. In therapeutic doses 
in female patients, Whitelaw327 • 328 reported 
that 25 mg. twice daily of chlorpromazine 
1 to 3 days prior to expected ovulation 
produced a delay in ovulation and men-
struation as judged by suction biopsy find-
ings and basal body temperatures. When 
the medication was started just after men-
struation, prolongation of the cycle was not 
noted. He postulated that chlorpromazine 
depresses the hypothalamus, interfering 
with pituitary gonadotropin output, when 
it is given just prior to ovulation. The fact 
that daily use of the drug from the time of 
menses to the next expected ovulation did 
not interfere with the latter suggests that 
tolerance may develop to this phenomenon. 
Some phenothiazines, espeCially in large 
dosage, may produce amenorrhea. GO 
Suzuki and associates"98 gave chlorprom-
azine intramuscularly over 5 days ( 225 
mg. total) to various gravid and nongravid 
and postclimacteric women and measured 
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the urinary excretion of various hormones. 
Chlorpromazine caused a reduction in the 
urinary levels of gonadotropin, estrone, es-
tradiol, estriol, pregnanediol, and total 17-
hydroxycorticoids. Total 17 -ketosteroids 
was not effected in pregnant, toxemic, as 
well as postclimacteric women. The drug 
suppressed the excretion of gonadotropin 
in pregnant women, suggesting it inhibits 
the secretion of chorionic as well as pitui-
tary gonadotropin. Chlorpromazine also 
inhibited the response of rabbit ovaries to 
gonadotropin in the Friedman test. The 
authors felt that the reduction in estrogen 
and progesterone levels was due to central 
factors as well as reduction of function of 
peripheral endocrine glands. 
Hooper, Welch, and Shackelford,148 re-
ported that 26 of 100 female psychiatric 
patients receiving various tranquilizers de-
veloped abnormal lactation. The drugs in-
cluded chlorpromazine, proclorperazine, 
thioridazine, trifluoperazine, fluphenazine, 
meprobamate, and combinations of these. 
The incidence of abnormal lactation paral-
leled drug dosage. Abnormal lactation did 
not occur when antidepressants were com-
bined with the tranquilizer. One false posi-
tive pregnancy test result was encountered 
in a patient taking 30 to 35 mg. of proclor-
perazine per day. Lactation has also been 
observed by others with reserpine and 
trimeprazine. Sulman292 used the nipple 
test in the male rat to determine the effects 
of chlorpromazine, reserpine, and other 
drugs for mammotropic activity which 
might serve as a prediction of lactogenic 
activity in man. He ascribed the lactogenic 
activity of chlorpromazine and reserpine as 
caused by hypothalamic depression. 
Scott and N ading277 compared the 
relative effectiveness of a series of pheno-
thiazines in causing release of melanocyte-
stimulating hormone in intact and hypo-
physectomized frogs. All drugs tested in 
the hypophysectomized frogs were without 
effect. It was shown that all of the various 
phenothiazines tested were effective in in-
tact frogs in releasing melanocyte-stimulat-
ing hormone. A striking correlation was 
Tranquilizing drugs 617 
evident between this research in frogs and 
the report of Ayd10 in which he compared 
the potency of the same agents in the treat-
ment of psychiatric disorders in man. The 
relative ranking for the ten drugs was 
almost identical. Any Significance of this 
hormone in man is of course -unknown. 
Brauchitsch40 has reviewed the extensive 
literature on the effects of various tranquil-
izing drugs, including chlorpromazine and 
reserpine, on the endocrine system. He pro-
poses that the first phase of action is an 
increase in adrenocortical activity and a 
decrease in thyroid activity. In the second 
phase, a reversal of endocrine equilibrium 
takes place depending upon dose, duration 
of treatment, etc. Thyroid activity gradu-
ally returns toward normal. 
The interaction between chlorpromazine 
and antidiuretic hormone is not completely 
known. Moyer and co-workers231 reported 
that acute administration of chlorproma-
zine parenterally usually increases urinary 
flow in normal man and dogs indepen-
dently of a change in renal hemodynamics. 
The drug appeared to increase sodium and 
water excretion. Parrish and Levine242 
found that after intravenous administration 
of chlorpromazine (25 mg.) to various con-
valescent patients free of renal disease, the 
effective renal plasma flow and glomerular 
filtration rate rapidly decrease, with no 
change in the ratio of clearance of sodium 
or potassium to clearance of inulin. There 
was a concomitant increase in urine output 
and a decreased urinary excretion of an 
antidiuretic substance. They suggested this 
may be due to either a direct effect on the 
renal tubule or an indirect effect by way 
of central depression of antidiuretic hor-
mone release. CohenG2 also was able to 
show that chlorpromazine infused intra-
venously at 3.5 mg. per hour was an effec-
tive diuretic agent in normal individuals 
and in patients with cor pulmonale in con-
gestive failure. In normal subjects, the 
water diuresis was not accompanied by an 
electrolyte diuresis, but that in the pa-
tients with congestive failure was. Potas-
sium excretion did not change. With the 
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small doses of chlorpromazine used, the 
blood pressure did not change signincantly. 
The glomerular nltration rate rose in most 
of the congestive heart patients but not in 
the normal persons. 
The majority of reports suggest that 
chlorpromazine shows antidiuretic proper-
ties in hydrated rats. These include Meier, 
Briini, and Tripod,221 Kovacs and associ-
ates,188 Supek, Keckes, and Vojvodic,294,295 
and Tiwari, Jindal, and Jaiswa1. 306 On the 
other hand, Kivalo, Rinne, and Marjanenl7l 
observed a diuretic action and Dasgupta70 
no effect. Supek and colleagues294-296 noted 
that antidiuresis induced by nicotine in-
jection or posterior pituitary extract was 
signincantly prolonged by chlorpromazine. 
Tiwari, Jindal, and JaiswaPo6 compared 
various phenothiazines as well as morphine, 
pentobarbital and reserpine on both water-
induced and saline-induced diuresis. Within 
1 hour after injection, morphine, chlor-
promazine, and promazine showed antidiu-
retic effects, while the ethyl diethylamino 
analogue showed a diuretic response. Pro-
mazine was less effective than chlorproma-
zine, while morphine was the most anti-
diuretic. Reserpine in very small doses had 
no signincant effect. In saline-loaded rats, 
pentobarbital, proclorperazine, and di-
methylaminoethyl phenothiazine were 
diuretic, while chlorpromazine and proma-
zine were still antidiuretic. 
Biochemical mechanism of action. The 
substituted phenothiazines are adrenergic, 
cholinergic, and histaminergic blocking 
agents. Inasmuch as the adrenergic block-
ing effects predominate, the central adre-
nergic blocking properties of the substituted 
phenothiazines have been tacitly assumed 
by many to account for their central ac-
tions. That this may not be the only 
mechanism is suggested by the numerous 
studies, especially in vitro, of the wide-
spread biochemical effects of the pheno-
thiazines. Unfortunately, most published 
reports are based upon data in vitro ob-
tained at high concentrations (for in vivo) 
such as 1O-4M. Frequently, no appropriate 
physical controls (such as alteration of 
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surface tension, mitochondrial swelling, 
etc.) have been made. As a result, much of 
the literature data must be taken lightly. 
The studies reviewed are presented only 
as possible leads to the biochemical actions 
of these agents and should not be accepted 
as dennitive evidence of the mechanisms of 
action of the phenothiazines. 
One of the nrst suggestions on the bio-
chemical mechanisms of action of chlor-
promazine was that it produced uncoupling 
of phosphorylation from oxidation.1 Quastel 
and Quastel259 reviewed some of the 
evidence that chlorpromazine acts as an 
uncoupler. They have pOinted out that 
chlorpromazine has certain similarities to 
amobarbital and other barbiturates in this 
regard. Berger29, 30 demonstrated that 
chlorpromazine in concentrations of 2 x 
lO-4M was effective in uncoupling phos-
phorylation from oxidation in rat liver mito-
chondria. The drug, however, under similar 
conditions failed to uncouple with brain 
mitochondria. Chlorpromazine appeared to 
act at all of the steps along the electron 
transport chain. Interestingly, brain mito-
chondria had a greater ability to absorb 
chlorpromazine than liver mitochondria. 
Dawkins, Judah, and Rees72 showed that 
in vitro concentrations of chlorpromazine 
of 1 x lO-4M uncoupled the phosphoryla-
tion from oxidation of reduced cytochrome 
c. The drug did not affect the phosphoryla-
tions coupled to the prior steps in the elec-
tron transport chain. Chlorpromazine com-
petitively inhibited cytochrome oxidase. 
These effects were found in both rat brain 
and liver mitochondria. 
Bernsohn, N amajuska, and Cochrane31 
compared chlorpromazine, promazine, 
chlorpromazine sulfoxide, and prometha-
zine in ability to inhibit brain cytochrome 
oxidase and adenosine triphosphatase. In 
concentrations of lO-4M, chlorpromazine 
was slightly more effective than promazine 
and promethazine; chlorpromazine sulfox-
ide had no signincant inhibitory effect. The 
nndings with chlorpromazine are in agree-
ment with those of Abood.1 
Helper and associates133 determined the 
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effects in vitro of a large series of hetero-
geneous centrally active drugs on rat brain 
and liver succinoxidase activity. In suffi-
cient concentration, all drugs inhibited ac-
tivity; however, chlorpromazine was most 
effective, followed by promazine, pro-
methazine, and reserpine. In all cases, 
cytochrome oxidase was more sensitive and 
succinic dehydrogenase less sensitive to 
inhibition than the complete succinoxidase 
system. Brain succinoxidase was more re-
sistant to inhibition than liver succinoxi-
dase. The authors did not feel that inhibi-
tion of this system was the mechanism of 
action of all the tranquilizers studied. 
If chlorpromazine were a very effective 
uncoupling agent in vivo, one would ex-
pect the brain levels of high energy phos-
phates to decrease. The reverse is actually 
true, indicating that utilization is more de-
pressed than synthesis. Grenell, Mendelson, 
and McElroy119 showed that chlorproma-
zine in large doses given to rats had no 
effect on the oxygen uptake or the in vitro 
rate of acetylation of sulfanilamide. It did, 
however, induce a marked increase in 
adenosine triphosphate levels, indicating a 
decrease in utilization. The greatest in-
crease was in the midbrain, followed by 
cerebellum, cerebral cortex, and medulla. 
Subsequently, Weiner and Huls325 showed 
that chlorpromazine had no effect or ele-
vated slightly the levels of adenosine tri-
phosphate and creatine phosphate depend-
ing upon how the animals were sacrificed. 
Their results suggested that chlorpromazine 
depressed the utilization of brain adenosine 
triphosphate so that a given stimulus re-
sulted in less use of labile phosphate. The 
biochemical effects in vitro of chlorproma-
zine, reported as interfering with oxidative 
enzyme systems and uncoupling of oxida-
tive phosphorylation, therefore, appear un-
related to its primary action in vivo. 
Depending upon the experimental condi-
tions, chlorpromazine can decrease or in-
crease the uptake of p32 inorganic phos-
phate into the brain phosphatides. Wase, 
Christensen, and Polley322 reported that 48 
hours after administration of large doses 
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of chlorpromazine to rats, there was a re-
duction in the incorporation of phosphate 
into the phosphatides of the hypothalamus 
and cortex. After 24 hours, the hypothala-
mus showed increased incorporation. In an 
in vitro study using guinea pig brain slices, 
Magee, Berry, and Rossiter213 found that 
chlorpromazine in concentrations of lO-4M 
stimulated the uptake of p32 into phospha-
tidyl serine, inositol phosphatidyl, and 
pOSSibly phosphatidic acid. The labeling of 
phosphatidyl ethanolamine was unaffected, 
while that of lecithin was reduced. Ansell 
and Dohmen8 showed that chlorpromazine 
given in vivo to rats also caused a marked 
reduction of p32 incorporated into lecithin 
as well as phosphatidyl ethanolamine. 
Strickland and Noble290 studied the incor-
poration of p32 into different areas of the 
guinea pig brain following chlorpromazine 
both in vitro and in vivo. Chlorpromazine 
in concentrations of lO-4M had no effect on 
the incorporation of p32 into phosphatides 
of slices of liver, kidney, or pancreas but 
caused a definite increase in labeling in the 
brain. Brain homogenates and especially 
mitochondria took up the labeled phos-
phate mainly in phosphatidic acid, inositol 
phosphatide, and possibly phosphatidyl 
serine. No effect was noted on the incor-
poration of p32 by lecithin and phosphati-
dyl ethanolamine in contrast to the results 
of Magee, Berry and Rossiter. In vitro, all 
areas of the brain except the caudate nu-
cleus and white matter of the cerebellum 
showed increased labeling after chlorprom-
azine in concentrations of lO-4M. In vivo, 
chlorpromazine-treated cats showed twice 
as high uptakes of p32 into phosphatides in 
all areas of the brain studied. 
In high concentrations in vitro, the 
phenothiazines inhibit oxygen consumption 
of rat brain slices and alter the distribution 
of glutamic acid and y-aminobutyric acid 
between the brain slice and the incubation 
media.92 Although its significance is un-
known, chlorpromazine in large doses to 
cats prevents the methylation of C14-labeled 
histamine by the brain. 326 Cupric chloride 
has a similar effect. 
620 Domino 
Chlorpromazine and methoxypromazine 
given in large doses to rats significantly in-
crease brain glutamine levels in contrast to 
meprobamate and reserpine. A rise in brain 
alanine was also produced by the adminis-
tration of these phenothiazines as well as 
by various convulsants. In contrast, pheno-
barbital produced a fall in both glutamic 
acid and y-aminobutyric acid in the brain. 
Acetazolamide had a similar effect, but 
diphenylhydantoin did not affect either 
glutamic acid or y-aminobutyric acid 
levels. 76 
The chemical reactivity of the pheno-
thiazine molecule is also evidenced by 
various reports in the literature that chlor-
promazine complexes flavine adenine nu-
cleotide, chondroitin sulfate, heparin, and 
t~.~ brain ganglioside strandin. The latter 
agent is distributed in the highest concen-
trations in the cerebral cortex. Little is 
known of the physiologic significance of 
strandin other than its inhibition of blood 
clotting and viral hemagglutination. Harris, 
Saifer, and Volk127 have suggested that the 
high concentrations of strandin in the cere-
bral cortex protect the cortex from depres-
sion by chlorpromazine and related pheno-
thiazines. 
Evidence is available that chlorpromazine 
has marked interactions with neurotrans-
mitter substances producing effects other 
than simple block of receptor sites. For 
example, Mariani and Vertua2l6 have shown 
that chlorpromazine reduces the binding of 
serotonin by various tissues of the guinea 
pig both in vitro and in vivo. Pletscher and 
Gey253 studied the effects of chlorproma-
zine on the precursors of serotonin and 
catecholamines. Chlorpromazine reduced 
the 5-hydroxytryptophan-induced rise of 
serotonin in the rat brain in vivo and in 
isolated brain. The drug also increased the 
blood:brain ratio of C14-labeled 5-hydroxy-
tryptophan and C14-labeled 3:4-dihydroxy-
phenylalanine. Inasmuch as decarboxyla-
tion of aromatic amino acids was not 
inhibited by chlorpromazine in vivo, these 
investigators concluded that chlorproma-
zine reduced the uptake of aromatic amino 
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acids in the brain. Chlorpromazine and 
chlorprothixene do not affect the content of 
endogenous rat brain serotonin, dopamine, 
and norepinephrine. lo9 However, these 
agents antagonized the release of brain 
amines by reserpine and their increase 
after iproniazid or 5-hydroxytryptophan. 
They suggested that the phenothiazines 
and related drugs act by decreasing the 
permeability of the storage granules for 
these brain amines. Guth and Spirtes123 
have also suggested that chlorpromazine 
affects permeability. Furthermore, they 
have offered evidence of a selective accu-
mulation of chlorpromazine in the hypo-
thalamus and, in particular, in mitochon-
dria. The release of acetylcholine from 
synaptic vesicles was inhibited by very 
small concentrations of chlorpromazine. 
This may account for the observation of 
Tatlow, Fisher, and Dobkin304 that chlor-
promazine suppresses acetylcholine release 
from the eat's cortex as well as in cortical 
tissue removed at the time of lobotomy in 
schizophrenic patients. 
Potentiation of the action of various 
drugs. The phenothiazines are known to 
potentiate the actions of various drugs such 
as the barbiturates, narcotics, and anesthet-
ics. This effect is dose dependent, and in 
man in usual therapeutic doses, one may 
or may not obtain potentiation. Moyer2 ;]O 
felt that this potentiation was extremely 
variable. In some patients, there was a 
marked effect, while in others it was 
minimal. The potentiating actions of chlor-
promazine and promethazine on the res-
piration of man have been recorded by 
Reckless264 with a spirometer. Both pheno-
thiazines potentiated the actions of 
thiopental, diethyl ether, tubocurarine, and 
narcotic analgesics including meperidine 
and morphine. Depending upon the type 
of neuromuscular blocking agent, potentia-
tion or antagonism is observed as well as a 
direct blocking effect in very large doses. 2U1 
Fraser and Isbell101 showed that chlor-
promazine (25 mg. intramuscularly or 50 
mg. orally) increased the intensity of the 
miotic and sedative effects of 10 and 30 
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mg. of morphine subcutaneously in post-
addicts. Interestingly, the combination did 
not depress the respiratory minute volume 
any more than morphine alone. Reserpine 
(1 mg.) seemed to enhance the sedative 
effects of 30 mg. of morphine. 
The interaction between phenothiazines, 
reserpine, meprobamate, and ethyl alcohol 
given to 4 young adults was studied by 
Burge.54 Except for meprobamate, the 
drugs tested potentiated depressant effects 
of alcohol. Tipton and colleagues305 deter-
mined the effects of chlorpromazine, reser-
pine, atropine, and hexamethonium on 
alcohol blood levels in rabbits. After oral 
administration of ethyl alcohol, chlorprom-
azine alone enhanced the levels of alcohol 
in the blood. These investigators concluded 
that this effect was not due to an increase 
in absorption but was related to inhibition 
of alcohol metabolism. In fact, Khauw168 
has shown that chlorpromazine in vitro 
inhibits alcohol dehydrogenase. Chlorprom-
azine potentiation in vivo in man of the 
effects of alcohol has been repeatedly ob-
served. 33G 
Several studies comparing the structure 
and potentiating activity of the phenothia-
zines have appeared. Dobkin80 compared 
various phenothiazine derivatives in their 
ability to prolong thiopental anesthesia in 
the dog. Unfortunately, different doses of 
the various drugs were used, so that it was 
impossible to compare them quantitatively. 
Nevertheless, in the doses used, promazine, 
propiomazine, and prothipendyl more than 
doubled the hypnotic effect of thiopental. 
Levomepromazine, imipramine, and meth-
dilazine also caused a consistent prolonga-
tion of thiopental anesthesia. Mepazine, 
proclorperazine, and trifluoperazine had no 
effect on the duration of thiopental anes-
thesia. 
Jindel, Tiwari, and Kherdikar157 com-
pared the effects of equal doses (by weight) 
of a series of substituted phenothiazines 
and related drugs on pentobarbital sleeping 
time in mice. Chlorpromazine was quite 
effective, although its derivative lacking 
the dimethyl group on the terminal nitro-
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gen and position 2 chlorine was also very 
effective. Promethazine was less effective 
than chlorpromazine. Replacement of the 
phenothiazine ring with phenoxazine re-
duced potency as well. Of interest is the 
fact that those compounds which potenti-
ated pentobarbital sleeping times also 
showed antidiuretic effects in saline-in-
duced diuresis in rats. Those compounds 
which had no effect or reduced pentobar-
bital sleeping times had a diuretic effect 
against saline-induced diuresis. The au-
thors suggest these findings may be related 
to the varying ability of the phenothiazines 
to release antidiuretic hormone. It is in-
teresting also to note that others have 
shown the injection of antidiuretic hormone 
prolongs barbiturate sleeping time. Cer-
tainly, it seems most unlikely that antidiu-
retic hormone release is the only factor 
involved in phenothiazine potentiation of 
pentobarbital anesthesia, but it may be 
contributory. Further experiments obvi-
ously are necessary. 
Metabolic fate. The extremely complex 
metabolic fates of the substituted pheno-
thiazines are only partially known. Re-
cently, a selected annotated reference list 
has been made available (by the Psycho-
pharmacology Service Center313 ) which 
summarizes some of the hundreds of refer-
ences available on metabolic studies and 
the analytic methods used for clinically 
useful phenothiazines. Even a casual sur-
vey of this literature provides one with a 
formidable impression of the complexity of 
the problem. 
The phenothiazines are metabolically 
highly reactive. Animal studies are avail, 
able on the various metabolites of pheno-
thiazine itself. These metabolites vary from 
species to species. Substitutions on the 
phenothiazine ring add further substrates 
which may be sites for metabolic altera-
tion. Salzmann and Brodie270 identified 
chlorpromazine sulfoxide as a metabolite of 
chlorpromazine in both the dog and hu-
man. In 2 patients taking 900 mg. of chlor-
promazine orally a day, only negligible 
amounts of unchanged drug and about 5 
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per cent as the sulfoxide appeared in the 
urine. In dogs, only 10 to 15 per cent of the 
chlorpromazine could be accounted for as 
the sulfoxide. The sulfoxide could possibly 
be further metabolized to the sulfone. 
Chlorpromazine sulfoxide was less sedative 
and produced less hypotension than the 
parent compound. These investigators 
noted that chlorpromazine was metabolized 
slowly, in part due to its high degree of 
localization in various tissues. Of particu-
lar significance was its high concentration 
in dog brain, reaching 70 times the level in 
plasma. 
Although humans and dogs excrete 
somewhat similar urinary metabolites of 
chlorpromazine, there are some qualitative 
and quantitative differences. ll3 Urine sam-
ples from humans receiving 600 mg. of 
chlorpromazine a day and dogs receiving 8 
mg. per kilogram a day orally were ana-
lyzed. Dogs excreted nine phenothiazines 
in moderate amounts and a tenth in traces. 
The compounds identified included the fol-
lowing, expressed as the percentage of the 
administered dose: desdimethyl chlorprom-
azine sulfoxide, 1.1 per cent; desmono-
methyl chlorpromazine sulfoxide, 5.1 per 
cent; chlorpromazine sulfoxide, 5.1 per 
cent; and chlorpromazine or promazine, 2.8 
per cent. Humans excreted nine com-
pounds, which included the following, ex-
pressed as the percentage of the adminis-
tered dose: desdimethyl chlorpromazine 
sulfoxide, 3.7 per cent; desmonomethyl 
chlorpromazine sulfoxide, 1.8 per cent; 
chlorpromazine sulfoxide, 0.4 per cent; and 
chlorpromazine or promazine, 6.1 per cent. 
Chlorpromazine sulfoxide concentrations 
were not large in either man or dog. Hu-
man urine contained two series of phenolic 
derivatives, the dog only one. 
Huang, Sands, and Kurland150 found 
chlorpromazine glucuronides as the major 
urinary metabolites of psychotic patients 
given 100 to 400 mg. of chlorpromazine 
three times a day. Chlorpromazine sulfox-
ide and the hydroxy derivatives were pres-
ent in smaller amounts. Unchanged chlor-
promazine was found in very small quan-
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tities. Glucuronide formation appeared to 
be the most important pathway of chlor-
promazine degradation. After discontinua-
tion of the drug, the glucuronides were 
detectable in the urine for as long as 30 
weeks. It seemed that those patients ex-
creting the glucuronides for a long period 
regressed more slowly. 
Forrest, Forrest, and Mason98 have re-
viewed the various urine tests for detecting 
phenothiazines and related substances. 
They pOinted out that the partially oxi-
dized, highly reactive intermediary drug 
metabolites of phenothiazines probably ac-
count for much more of the metabolism of 
the phenothiazines than sulfoxide forma-
tion. Other metabolites, partly free and 
combined glucuronic acid conjugates in-
cluding oxidative changes in the nucleus, 
and demethylation of the side chain have 
been reported. During continuous drug 
administration to man, approximately half 
of the daily intake of chlorpromazine ap-
pears in the urine. Lesser amounts occur 
in the urine after Single doses. The balance 
is excreted in the feces, and some resides 
in various body depots. Only 20 per cent 
of the amount of chlorpromazine contained 
in the urine is in the form of solvent ex-
tractable metabolites. The balance of 80 
per cent of urinary drug is in the form of 
polar, intermediary oxidative metabolites 
of various types of hydroxylated deriva-
tives. The absolute as well as the ratio of 
individual drug metabolites varies with 
each phenothiazine and to a lesser extent 
in different patients on the same pheno-
thiazine. Forrest, Forrest, and Mason did 
not observe any differences in therapeutic 
efficacy and urine color tests for intramus-
cular or oral doses of chlorpromazine in the 
same patient. When spansules were used 
repeatedly, however, a 30 per cent increase 
in dose was necessary to obtain the same 
previous clinical effect and urinary drug 
level according to test I of Forrest. Forrest, 
Forrest, and Mason98 have summarized the 
qualitative urinary color tests for the rapid 
identification of various phenothiazines and 
related substances. Tests I and II are for 
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chlorpromazine, promazine, and mepazine. 
The tests utilize 1 ml. of urine and 1 ml. of 
20 parts 5 per cent ferric chloride and 
80 parts 10 per cent sulfuric acid. Test III 
is for thioridazine. It consists of mixing 1 
ml. of urine and 1 ml. of a test solution 
containing 2 parts 5 per cent ferric chloride 
and 98 parts 30 per cent sulfuric acid. Test 
IV is for imipramine. It consists of mixing 
0.5 ml. of urine with 1 ml. of a test solution 
containing 25 parts 0.2 per cent potassium 
dichromate, 25 parts 30 per cent sulfuric 
acid, 25 parts 20 per cent perchloric acid, 
and 25 parts 50 per cent nitric acid. Test 
V is for most phenothiazines such as chlor-
promazine, promazine, triflupromazine, pro-
clorperazine, trifluoperazine, perphenazine, 
fluphenazine, thiopropazate, acetophena-
zine, mepazine, thioridazine, promethazine, 
and others. This ferric, perchloric, and 
nitric acid (universal) test consists of mix-
ing 1 ml. of urine and 1 ml. of test solution 
which consists of 5 per cent ferric chloric 
acid, 45 parts 20 per cent perchloric acid, 
and 50 parts 50 per cent nitric acid. In all 
tests, the color reaction must be read 
promptly and compared to a color chart in 
order to estimate the daily dose of pheno-
thiazine ingested. Numerous ketonic and 
aldehydic substances and other drugs may 
interfere with these color tests; therefore, 
these must be kept constantly in mind. 
Some of the more obvious sources of false 
positives include (1) p-aminosalicylic acid 
in tuberculosis patients, (2) phenylketon-
urics, (3) patients on high doses of estro-
gens, and (4) patients with impaired liver 
function. 
Forrest and Forrest97 have reported that 
urine samples of chronic mental patients 
who received daily doses of 600 mg. of 
chlorpromazine for a long time showed 5 
per cent excretion as the sulfoxide, 0.75 per 
cent as unchanged chlorpromazine, and 0.5 
per cent as thionium hydrOxide. Discon-
tinuation of the drug showed that un-
changed chlorpromazine was excreted in 
the urine in trace amounts for several 
weeks, and thionium hydroxide for many 
weeks and months. Forrest and Forrest99 
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subsequently reported that after drug dis-
continuation, trace amounts may be de-
tected in the urine for periods up to 6 
months. 
Huang and associates149 , 150 studied the 
urine of chronic schizophrenic patients 
given chlorpromazine in doses of 100 to 
400 mg. three times daily for the pres-
ence of free chlorpromazine and its three 
sulfoxides, including chlorpromazine sul-
foxide, and its demethylated analogues, 
nor-I-chlorpromazine sulfoxide and nor-2-
chlorpromazine sulfoxide. The average ex-
cretion of these substances was from 1.31 
to 20.54 per cent of the administered dose. 
Of this, free chlorpromazine was less than 
1 per cent, while the sulfoxides ranged 
from 1 to 18 per cent of the administered 
dose. After medication was stopped, free 
chlorpromazine and its sulfoxides disap-
peared from the urine in 5 days. Haynes132 
analyzed the urinary excretory products 
during and after cessation of 200 to 800 
mg. of chlorpromazine administered daily 
for periods of 4 to 11 days. The products 
which were ether soluble included free and 
bound chlorpromazine and its sulfoxide. 
After drug discontinuation, the urinary me-
tabolites dropped significantly after the 
first day but continued to be present in 
small amounts for 6 days afterward. 
Posner257 suggests that on theoretic 
grounds, chlorpromazine can be metabo-
lized to many different compounds. These 
include the sulfoxide, demethylated sulfox-
ides, N-oxide, phenolic derivatives, and 
conjugates of these with glucuronide. It is 
possible that some of these metabolites 
might contribute to the pharmacologic ac-
tivity of the phenothiazines. To date, the 
sulfoxide derivative is known to be much 
less potent, but other metabolites might be 
more active. Posner has noted as many as 
fifteen different metabolites of chlorproma-
zine or promazine on paper chromatograms 
of human urine. He postulates some of 
these include modification of the side chain, 
including 3-hydroxy, 3,7-dihydroxy, the 3-
hydroxy sulfide, and the 3,7-dihydroxysul-
fide. 
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Phenothiazines can apparently cross the 
human placenta. Behn, Fram, and Fret-
wurst22 reported that phenothiazine deriva-
tives could be detected in the urine of 
newborn babies whose mothers had been 
given 50 mg. of chlorpromazine and pro-
methazine within 30 minutes prior to de-
livery. About 0.5 to 1 per cent of the dose 
given the mother was in the child. Most of 
the excretion in the child occurs within the 
first 48 to 60 hours. The concentration of 
the drug in the fetus depends upon the 
time interval between administration to 
the mother and delivery. Marx21s has re-
viewed the literature on the placental trans-
fer of many drugs, including the pheno-
thiazines. Every known sedative, hypnotic, 
and anesthetic drug which passes the 
blood-brain barrier apparently also passes 
the placental barrier. 
The pharmacologic effects of chlorprom-
azine apparently are the result of its 
presence in appropriate tissue sites. Chris-
tensen and Wase59 studied the distribution 
of S35-labeled chlorpromazine given intra-
peritoneally to mice. Radioactivity was 
rapidly and widely distributed, with the 
spleen and brain retaining the highest 
levels up to 5 days. Brain concentrations 
paralleled the degree of central nervous 
system depression. The maximal radioac-
tivity occurred in the brain and kidney 
before any other tissue. Wase, Christensen, 
and Polley322 further studied the accumula-
tion of S35-labeled chlorpromazine in the 
rat brain. The radioactivity was found in 
the lipid fraction, none in the protein frac-
tion. In contrast, in the liver, about 5 to 10 
per cent was protein bound. U sing a 
chemical technique for converting chlor-
promazine to the sulfoxide and measuring 
it spectrophotometrically, Wechsler and 
Roizin324 were unable to find a high con-
centration of chlorpromazine in the rat 
brain. Assuming the results of both investi-
gators to be valid, this would suggest that 
the S35 label from chlorpromazine was ex-
changed for other tissue sulfur or that 
chlorpromazine in the brain is not easily 
extractable or converted to the sulfoxide. 
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Walkenstein and Seifter321 studied the tis-
sue distribution of S35 promazine in dogs 
and rats. A large intraperitoneal dose of 
S35 promazine given to the dog was ex-
creted about 70 to 80 per cent in the urine 
and 20 to 30 per cent in the feces in about 
7 days as measured by the radioactivity. 
Rats were also given the drug orally and 
intraperitoneally. Fifteen minutes after in-
jection, 50 per cent of the blood radioac-
tivity was due to metabolically altered 
drug. No unchanged promazine was found 
in the blood after 24 hours. Highest con-
centrations were in the lung, liver, spleen, 
and kidney. Concentrations in the brain 
were low. This is in striking contrast to the 
data of Christensen and Wase on S35_ 
labeled chlorpromazine in the mouse. 59 In 
the urine, the promazine appeared un-
changed as the monodemethylated com-
pound and the corresponding sulfoxides. 
All of these compounds accounted for 10 
per cent of the administered dose. Paren-
teral administration of promazine gave 
higher tissue levels than oral administra-
tion. 
The Russian investigator Fyodorov105 has 
studied in detail the fate of S35-labeled 
chlorpromazine, promazine, and chlormep-
azine in various species of animals and 
man. In the dog, the highest concentration 
of radioactivity due to S35-labeled chlor-
promazine was found in the lung, followed 
by the adrenal, liver, intestine, and brain. 
Only traces occurred in the blood. Radio-
activity in the bile was high. There was a 
difference in the distribution of chlorpro-
mazine depending on whether it was 
given intramuscularly or orally. Upon oral 
administration, a large amount of the 
chlorpromazine circulates in a closed en-
terohepatic route involving absorption from 
the gastrointestinal tract, portal transport 
to the liver, liver excretion via the bile, etc. 
As a result, less enters the systemic circula-
tion than when it is given intramuscularly. 
Fyodorov suggests that this may indicate a 
greater incidence of liver toxicity with oral 
than with parenteral administration. Even 
after intramuscular' administration, some 
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chlorpromazine is excreted via the bile. 
Species and the type of substituted pheno-
thiazine also determine the tissue distribu-
tion of the drug. In man, S35 chlorproma-
zine given intramuscularly is excreted 
slowly. It disappears, however, from the 
blood very rapidly. Reasonable blood 
levels are present only 2 to 3 hours after 
injection. After 120 hours, only 16.3 per 
cent of the radioactivity appears in the 
urine, and after 192 hours, 20.2 per cent is 
excreted in the feces. Hollister, Traub, and 
Prusmack146 also report high biliary excre-
tion levels of thioridazine given orally to 
schizophrenics. 
Hetzel137 reported that after 100 mg. of 
promazine given orally to 2 human sub-
jects, serum levels of 0.5 }Lg per milliliter 
were observed at 1 hour, A total of only 
8.8 per cent of the dose was recovered in 
the urine after 24 hours. Oral administra-
tion of 25 mg. of promethazine to 2 hu-
man subjects resulted in 7.5 and 10.4 per 
cent recovery of the drug in 24 hours. 
Eiduson, Geller, and Cohen90 have 
studied the excretion and metabolism of 
S35 ring-labeled thioridazine in humans. 
Upon oral administration of 200 to 400 mg. 
of the drug, the serum levels rose to a peak 
in 2 hours and were maintained for 6 hours 
after ingestion. Detectable blood levels 
were observed even 96 hours later. Never-
theless, most of the phenothiazine disap-
peared rapidly from serum. Approximately 
30 per cent of the original dose was ex-
creted in the urine and 50 per cent in the 
Jeces. Over 60 per cent was found in the 
bile fluid of a patient with a bile duct can-
nula. The peak excretion in bile occurred 4 
hours after ingestion of 200 mg. of the 
labeled compound. Serum was cleared most 
rapidly, with about 10 per cent of the origi-
nal dose appearing in venous blood at 2 to 
4 hours. The urinary chromatograms indi-
cated at least twelve different metabolites 
of this compound in man. 
An extremely interesting study on the 
role of drug metabolism in causing photo-
sensitivity in two different species has been 
reported by Whitten and Filmer.33o When 
TranqUiliZing drugs 625 
phenothiaZine itself was administered to 
young cattle as an anthelmintic, photo-
sensitized keratitis was observed. Similar 
keratitis was not observed in sheep main-
tained under the same circumstances. It 
was found that the sulfoxide of phenothia-
zine found in the blood of calves was also 
in high concentrations in the aqueous 
humor of the eyes. Sheep do not form the 
sulfoxide, and consequently, the aqueous 
humor does not contain it. These animals 
do not exhibit photosensitization, while 
young cattle do! Could some human pa-
tients showing photosenSitivity to the sub-
stituted phenothiazines have a scheme of 
phenothiazine metabolism more like young 
cattle, while those not showing photosensi-
tivity have one more like the sheep? 
Physical dependence. Although some re-
ports suggest that withdrawal of chronic 
phenothiazine therapy has no Significant 
deleterious effect,2G9 the majority of reports 
are to the contrary (see study and review 
of the literature by Gross and col-
leagues121 ). The question arises as to 
whether these exacerbations in illness fol-
lowing drug withdrawal are related to 
physical dependence to the phenothiazines. 
Boyd37 has described withdrawal symptoms 
in rats chronically treated with chlorproma-
zine. In twin control experiments, young 
male albino rats were given increasing 
doses of chlorpromazine (1 to 200 mg. per 
kilogram) intramuscularly for 40 weeks. 
The animals developed tolerance to the 
sedative and lethal effects of chlorproma-
zine but no cross tolerance to pentobarbi-
tal. During chronic drug administration, 
the animals showed impairment of growth 
and fertility, although food and water in-
take and urine and fecal output were nor-
mal or greater than normal. The animals 
developed alkaluria and indicanuria, hypo-
chronic anemia, and leukocytosis. No 
change in plasma lipids was observed. The 
abrupt withdrawal of chlorpromazine at 
the end of the fortieth week was followed 
by hyperkineSia, diarrhea, and occasionally 
death. Ten days after abrupt drug with-
drawal, the animals began to grow and 
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regain virility. The anemia and leukocyto-
sis disappeared by the twenty-first day, and 
the animals were eating and excreting nor-
mally after about 40 days. 
In man, the phenothiazines generally are 
not considered to produce any significant 
physical dependence and withdrawal 
symptoms. One exception is the report by 
Brooks.49 He noted a marked exacerbation 
of mental symptoms and muscular aches 
and pain, insomnia, and nausea upon 
abrupt drug withdrawal of a group of se-
verely disturbed schizophrenic women who 
had been on prolonged periods (18 to 44 
months) of chlorpromazine and reserpine. 
Thirteen of the 28 patients withdrawn were 
suffering symptoms similar to moderate 
withdrawal from morphine on the third 
day after the medication stopped. Another 
report suggesting possible withdrawal 
symptoms is that of Bennett and Kooi. 26 
These investigators compared the thera-
peutic effectiveness and toxicity of chlor-
promazine, mepazine, perphenazine, pro-
clorperazine, triflupromazine, and pheno-
barbital using a double blind procedure in 
30 male schizophrenics. Prolonged heavy 
dosage of chlorpromazine, perphenazine, 
proclorperazine, and triflupromazine pro-
duced abnormal theta and delta changes 
in the electroencephalograph which cor-
related with drug-induced parkinsonism 
and clinical remission. No hepatiC or hem-
atologic toxicity was observed. After abrupt 
withdrawal of medication (by double 
blind substitution of a placebo capsule), 
there was a reaction delayed 4 to 6 days, 
after which 8 of the patients on various 
phenothiazines developed nausea, giddi-
ness, vomiting, tremulousness, and delu-
sions which were less elaborate than pre-
viously. The patients spontaneously re-
ported that they suspected a change of 
medication. On resumption of the original 
medication, this symptomatology ceased 
within 3 days. These effects are hardly 
characteristic of other forms of drug with-
drawal. The prolonged delayed reaction 
would suggest an exacerbation of the basic 
psychopathologic state except that its char-
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acter was modified. Electroencephalo-
graphic tracings during the drug with-
drawal period did not show any evidence 
of major paroxysmal discharge, as has been 
observed with other drugs producing with-
drawal symptoms such as the barbiturates, 
alcohol, meprobamate, or narcotics such as 
morphine. In monkeys, the administration 
of chlorpromazine subcutaneously in in-
creasing doses to 2 mg. per kilogram, four 
times daily for a total of 45 days does not 
produce any obvious symptoms upon 
abrupt withdrawal. Some tolerance to the 
sedative effects was observed. '" A closely 
related congener of chlorpromazine, chlor-
prothixene, also does not produce signs of 
withdrawal after chronic administration of 
5 mg. per kilogram subcutaneously per day 
for 3 weeks followed by 5 mg. per kilogram 
twice daily for 4 additional weeks in mon-
keys. Tolerance to the intensity and dura-
tion of the sedative effects also was ob-
served. t It would appear, therefore, that 
physical dependence on the substituted 
phenothiazines is not marked compared to 
other classes of depressant drugs. 
Untoward effects and toxicity. The sub-
stituted phenothiazines produce numerous 
undesirable effects. 63 , 95, 114, 140, 174, 205 Some 
of these are due to their secondary phar-
macologic actions: lethargy, drowsiness, 
tachycardia, hypothermia, dryness of the 
mouth, orthostatic hypotension, lactation, 
and extrapyramidal symptoms. Although it 
is not certain, jaundice, agranulocytosis, and 
skin reactions including photosenSitivity 
are probably adverse effects related to 
drug allergy. Ayd11 , 12 has reviewed the un-
toward effects of the phenothiazines. He 
has pOinted out that potency correlates best 
with the extrapyramidal reactions and in-
versely with sedation, undesirable auto-
nomic effects, seizures, dermatitis, jaun-
dice, and agranulocytosis. Autonomic nerv-
ous system effects are most prevalent with 
the weaker drugs such as promazine, mep-
#D. McCarthy and C. Deneau: Personal communica-
tion, 1962. 
tC. Deneau: Personal communication, 1962. 
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azine, and methoxypromazine. They are 
much less frequent with the potent agents 
such as trifluoperazine and fluphenazine. 
The weaker drugs also cause more endo-
crine disturbances. 
Allergic reactions to the substituted phe-
nothiazines usually occur in the first few 
months of treatment. These include various 
forms of dermatitis, jaundice,s5 and agran-
ulocytosis. Most blood dyscrasias occur 
within the first few months of therapy. 
Korsp87 has reviewed this subject in detail. 
Agranulocytosis appears to be a definitely 
established reaction to chlorpromazine and 
promazine; there are reports that the other 
phenothiazines may have this action. If it 
is recognized and the drug stopped, the 
patient will recover completely. He should 
be treated with antibiotics but probably 
not corticosteroids. The reaction appears 
to be due to individual idiosyncrasy. Cross 
sensitivity to other phenothiazines may 
occur. Recovery usually is complete if man-
aged properly without residual bone mar-
row abnormality.20 More recently, Kahler1G2 
determined the incidence and mortality 
rate of patients with agranulocytosis caused 
by the phenothiazines. The incidence of 
agranulocytosis was 0.07 to 0.7 per cent of 
the total number of patients treated with 
various phenothiazines, with a mortality 
rate as high as 40 per cent. 
In an effort to determine the possible 
mechanisms of chlorpromazine-induced 
agranulocytosis, Pisciotta, Kohldahl, and 
Mally250 studied its effects on the uptake of 
H3-thymidine by granulocytes. Chlorprom-
azine inhibited the uptake of thymidine 
into granulocytes of normal cells but had 
no effect on its uptake by normoblasts 
when incubated with human bone marrow 
in vitro with H3-thymidine or uridine. 
The untoward effects of the phenothia-
zines and other tranquilizing agents in chil-
dren are similar to those in adults. Shaw280 
has reviewed these in detail. The substi-
tuted phenothiazines are most commonly 
used in children for the symptomatic re-
lief of nausea and vomiting. The most com-
mon adverse effects are extrapyramidal 
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symptoms. These may be confused with 
encephalitis, etc. The original dosage for 
children has been arrived at on a propor-
tional basis compared to the adult dose. 
Shaw suggests that children may have a 
greater sensitivity to these agents than 
adults, which might account for the numer-
ous reports of extrapyramidal symptoms. 
Proclorperazine has been espeCially im-
plicated in producing these effects. Pedi-
atric patients with acute infections and se-
vere dehydration may be extraordinarily 
sensitive. Treatment consists largely of 
cessation of the phenothiaZine medication, 
sedation with phenobarbital, and the ad-
ministration of antiparkinson drugs or caf-
feine. Sometimes extrapyramidal symptoms 
are protracted. The less common complica-
tions of phenothiazine therapy in children 
include jaundice, granulocytopenia, cu-
taneous eruptions, and hyperpyrexia. Chi-
coine58 reported on 25 cases of serious drug 
reactions to various phenothiazines in chil-
dren. The signs of intoxication included 
agranulocytosis, jaundice, extrapyramidal 
symptoms, somnolence, and semicoma 
which lasted for 8 hours to 4 days. 
Kelsey and associates'" observed three 
types of pathologic liver conditions asso-
ciated with chlorpromaZine. The most fre-
quent type was a diffuse inflammatory 
change associated with biliary stasis. The 
clinical picture was an obstructive type of 
jaundice with a moderate elevation of alka-
line phosphatase. None of the liver func-
tion tests associated with parenchymal liver 
damage were abnormal. The next type re-
sembled acute hepatitis with clinical evi-
dence of parenchymal liver damage as in-
dicated by elevated thymol turbidity and 
prothrombin deficiency. In the most un-
common type, early cirrhosis was observed. 
The patients showed marked azotemia and 
a clinical picture of severe and prolonged 
chronic liver disease. Danhof68 has re-
viewed some of the hypothesized mecha-
nisms for chlorpromazine-induced jaundice 
and studied in rats the role of various fac-
oQuoted by Moyer.'"· 
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tors which might lead to liver disease. 
Chlorpromazine-treated animals maintained 
on a choline-deficient diet failed to show 
diffuse fatty metamorphosis. No eosino-
philic infiltration or biliary canalicular 
plugging was evident. Chlorpromazine-
treated rats, however, showed an increase 
in bile viscosity and reduced bile volume. 
These effects appeared to be related to the 
decreased water intake of the animal. The 
author stressed the fact that no signs of 
jaundice could be obtained in these ani-
mals. Increased biliary pressures have been 
reported by Menguy and associates223 in 
the cholecystectomized dog given chlor-
promazine. An interesting attempt to pre-
vent jaundice resulting from chlorproma-
zine in man was reported by Dreyfuss. 86 
It was based on the hypothesis that in-
spissation of the bile was the mechanism 
of the jaundice. Patients treated with 
chlorpromazine were given large amounts 
of fluid. In the first 362 patients treated 
without extra fluids, the incidence of jaun-
dice was 4.4 per cent. After giving about 
2.3 L. of additional sweetened tea or water 
to each of another 588 patients, the inci-
dence of jaundice dropped to 0.34 per cent. 
Both groups of patients were otherwise 
similarly treated. 
Read, Harrison, and Sherlock263 de-
scribed the case histories of 4 women who 
developed obstructive jaundice after 1 to 
4 weeks on 75 mg. per day of chlorprom-
azine. Very high serum cholesterol levels 
and xanthomatous cutaneous deposits were 
noted in these patients. Clinical recovery 
was achieved in all cases, but serum cho-
lesterol and phosphatase levels did not re-
turn even 7 to 18 months later. The authors 
referred to the relationship of their find-
ings to primary biliary cirrhosis. Trifluo-
perazine has also been reported179 to cause 
cholestatic hepatitis with clinical, labora-
tory, and biopsy findings identical to those 
seen especially with chlorpromaZine but 
also with promazine, mepazine, proclor-
perazine, and other phenothiazines. 
Convulsions may be preCipitated by any 
of the phenothiazines. They can occur in 
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both epileptics and non epileptics. The less 
potent phenothiazines such as promazine 
and mepazine especially can produce con-
vulsions. In spite of this tendency to pre-
cipitate seizures, the phenothiazines can 
and should be used to control severe anx-
iety in the epileptic patient. For example, 
emotionally disturbed epileptics showed an 
excellent response to chlorpromazine. The 
drug was tolerated without marked alter-
ation in seizure frequency in most patients 
as long as anticonvulsant medication was 
maintained. 36 On chronic administration, 
the potentiation of barbiturate-induced 
drowsiness was negligible. The seizure-
lowering property of chlorpromazine has 
been studied in various patients subjected 
to electroshock therapy or chemically in-
duced convulsions. Interestingly, in thera-
peutic doses, this effect is not obvious. 
For example, single oral doses of 150 to 200 
mg. of chlorpromaZine 3 hours prior to 
electroshock therapy in psychiatric patients 
did not alter the course of the electroshock 
seizure, etc. Longer periods of sleep and 
occasional posttreatment hypotension were 
noted. 34 
The electroencephalographic or motor 
threshold for stroboscopic light flashes dur-
ing a timed infusion of a convulsant hex-
azole~ was not altered by increasing oral 
doses of chlorpromazine (150 to 800 mg. 
per day), reserpine (3 to 4 mg. per day) 
given chronically, or 100 mg. of azacyclonol 
given intravenously every 6 hours for eight 
doses in schizophrenic patients. 287 In addi-
tion to lowering seizure threshold, chlor-
promazine has also been reported to ele-
vate it. For example, it has been used in 
the treatment of status epilepticus. 71 
The extrapyramidal symptoms induced 
by the phenothiazines can frequently be 
quite dramatic. Aydll observed approxi-
mately a 39 per cent incidence of extra-
pyramidal reaction in 3,775 patients treated 
for 3 months to 6 years with various pheno-
thiazines. Akathisia (motor restlessness) 
occurred in approximately 21 per cent, 
"Fazole. 
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parkinsonism in 15 per cent, and dyskinesia 
(dystonic reactions) in 2 per cent of the 
cases. A correlation was found between the 
percentage occurrence of these reactions 
and milligram potency of the drugs as fol-
lows: chlorpromazine, 35 per cent; triflu-
promazine, 36 per cent; proclorperazine, 
45 per cent; thiopropazate, 44 per cent; 
perphenazine, 36 per cent; trifluoperazine, 
60 per cent; and fluphenazine, 52 per cent. 
Some interesting sex differences were ob-
served. Akathisia and parkinsonism oc-
curred twice as often in women as in men. 
In men, dyskinesia was twice as common as 
in women. Dyskinesia occurred earliest (90 
per cent within 4112 days), akathisia next, 
and parkinsonism last. Dyskinetic symp-
toms presented bizarre neuromuscular 
manifestations and could be mistaken for 
seizures, tetanus, meningitis, encephalitis, 
and poliomyelitis. These symptoms are 
promptly relieved by various antiparkin-
son ian drugs, including parenteral injec-
tions of 1 to 2 mg. of benztropine, biperi-
den, etc., as well as by diphenhydramine 
and dihydroxyphenylalanine208 and by caf-
feine." Ia 
Several authors have emphasized that 
the motor symptoms induced by pheno-
thiazines can mimic seizures or other seri-
ous diseases of the central nervous system. 
Shaw and colleagues281 reported a series 
of cases, including children and a few 
adults, who showed severe extrapyramidal 
symptoms (which they called seizures) 
frequently misdiagnosed for convulsions, 
poliomyelitis, infectious meningitis, tetanus, 
etc., after the use of various phenothia-
zines. Sometimes, these symptoms appeared 
within hours after small therapeutic doses. 
Scime and Tallant2 76 have reported that 
various extrapyramidal symptoms which 
may be mistaken for tetanus may occur 
with proclorperazine. They have empha-
sized that these can occur with small ther-
apeutic doses. The duration of the reactions 
may vary from Ij2 to 48 hours. To control 
mild reactions, phenobarbital was used. 
With severe reactions, amobarbital, pheno-
barbital, and benztropine were used to con-
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trol hyperactivity. No permanent afteref-
fects were noted in 8 patients having unto-
ward extrapyramidal effects from proclor-
perazine. 
Thioridazine appears to produce signifi-
cantly fewer untoward effects such as ex-
trapyramidal symptoms, lethargy and 
drowsiness, orthostatic hypotension, con-
vulsions, and photosensitivity than other 
phenothiazines."69 
Dobkin and Palkos2 compared various 
phenothiazines at different doses intrave-
nously as to their ability to depress salivary 
secretions induced by intravenous carbam-
inoylcholine and epinephrine. Levome-
promazine, trifluoperazine, proclorperazine, 
methdilazine, and prothipendyl reduced 
salivary secretions by 50 per cent in doses 
which produced drowsiness and a dry 
mouth. Promazine in the dose used had 
negligible effects on induced salivary flow. 
Patients who ingest an excess of chlor-
promazine present two different clinical 
pictures. The first is related to extreme 
somnolence. With prodding, the patient 
will arouse but promptly fall back into a 
deep sleep. In such a patient, slight hypo-
tension and respiratory depression may oc-
cur, but they are not a problem. The sec-
ond clinical picture is one of hypotension. 
This may be a mild to moderate fall in 
blood pressure whether the patient is con-
scious or not. The skin may be markedly 
gray but warm and dry. The nailbeds usu-
ally are still pink, and the pulse is strong 
but more rapid than normal. Respiration 
is usually slow and regular. Hypotension 
may be very severe; in this case, the pa-
tient may present symptoms of shock in-
cluding weakness, cyanosis, perspiration, 
and a rapid thready pulse. Treatment in 
each case is symptomatic. Inasmuch as 
chlorpromazine is an alpha adrenergic 
blocker, larger than usual doses of norepi-
nephrine may be necessary to maintain the 
blood pressure. Other phenothiazines may 
present similar clinical pictures. As the po-
tency of the compounds increases, there is 
a tendency for extrapyramidal symptoms to 
be present as part of the picture of acute 
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overdosage. For example, overdosage with 
trifluoperazine (140 mg. total dose) with 
suicidal intent can be manifested as gen-
eralized muscle spasms and stiffness of the 
legs, back, and neck, increased patellar re-
flexes, and torticollis with consciousness 
present. 14 
Rauwolfia alkaloids and 
related compounds 
Although preparations of the Rauwolfia 
alkaloids have been used for centuries in 
India for many illnesses, their widespread 
use in Western medicine began only after 
the isolation of reserpine from Rauwolfia 
serpentina by Mueller, Schlittler, and 
Bein233 in 1952. Since then, numerous alka-
loids have been isolated, some of which 
have been found therapeutically useful. 
With the exception of thebaine and papav-
erine, all of the Rauwolfia alkaloids are 
indole bases.274 
Some, such as yohimbine, have been well 
known for a long time, whereas others are 
relatively new; still others are yet to be 
identified. The chemistry of these alkaloids 
is very complex, which perhaps is Nature's 
way of prOViding hints of their complex 
pharmacology (see Bein23 ). 
Among the compounds frequently used 
therapeutically or of special theoretic inter-
est are those presented here. 
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St1'Ucture-activity relationships. A great 
deal of research activity has been devoted 
to the structure-activity relationship of the 
Rauwolfia alkaloids. In spite of the fact 
that many alkaloids have been isolated, re-
serpine still appears to be the most effec-
tive. Reserpine is a whitish crystalline pow-
der which is sparingly soluble in water. It 
dissolves readily in organic acids such as 
acetic and citric and can be diluted in this 
way. Lyophilized reserpine phosphate is 
directly soluble in water. 
On alkaline hydrolYSiS, reserpine yields 
reserpic acid, 3,4,5-trimethoxybenzoic acid, 
and methanol. Hydrolysis destroys pharma-
cologic activity. The compound can be re-
constituted from reserpic acid by methyla-
tion to methyl reserpate and subsequent 
trimethoxybenzoylation. Early reports sug-
gested that methyl reserpate was active, 
but this has not been confirmed. Changes 
in the esterifying acids in position 18 (re-
placing 3,4,5-trimethoxybenzoic acid) gen-
erally reduce activity. Minor alterations in 
the benzoic acid ester, however, result in 
compounds with somewhat similar activity. 
Rescinnamine is somewhat less potent cen-
trally as well as peripherally than reserpine. 
Syrosingopine also is less potent but has a 
more selective peripheral action than re-
serpine. Removal of the methoxy group in 
ring A of reserpine results in ll-desmeth-
A. Tertiary indole Rauwolfia alkaloids (naturally occurring 
and semisynthetic) 
a (I ~ I I N 
CIW/ :C/ (I 7CH, 
C) a-OCR] o ~ I . 11/ -OC-~ -OCH, CH30C "I 
OCH, 
Reserpine 
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O"(~NI )CH~H 
o C_og-O-OCHI 11/ ~ 
CH,OC I 
OCH, 
Deserpidine 
r)·-ON /~ ~/ ('" 
CH,O N 01 o~CR"_OCR' 
o gCR=CR- I-oCR, 11/ -0 ~ 
CR"OC I 
OCR, 
Rescinnamine 
caOO'NJ)(N 1 OCR" 
1 1 ~ O W O-OCOCR2CR 3 ~/ -OC-~ I_OCRa CRaOC 1 
OCRa 
S yrosingopine 
CH'~O,,/O 
~ (I ~CR" 
R 0 O-OCRa 
o -ot I_OCRa 11/ ~ 
CRaO-C 1 
OCR, 
M ethoserpidine 
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B. Synthetic derivatives 
CH'O-O(i 
CH,O-~ ~uN CHa 
-CH'-9H 
II CH, 
o 
Tetrabenazine 
Ro 4-1398 
CH~Oi 
CH,O-~ ~cNJ CH, 
-CH2-~H 
A CH, 
HO CH,CHa 
Ro 4-1284 
oxyreserpine or deserpidine. This com-
pound has qualitative and quantitative 
pharmacologic actions identical to reser-
pine. Interestingly, a shift of the position 11 
methoxy group on ring A of reserpine to 
position 10 (methoserpidine) has been 
claimed to produce a compound with a 
more selective peripheral action. 
Methoserpidine, the isomeride of reser-
pine, has been reported by Gros, Peter-
falui, and Jequier120 to have a hypotensive 
effect in man while lacking a central de-
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CHaO-O/ (/'1 
CHaO-~ ~cNJ 0 C,H, 
II / 
-C-N 
o "" /"" II C,H5 
H O-C-CHa 
Benzquinamide 
cHaO-("li CHaO-~)~ N CJ 0 C,H5 II / -C-N 
/"" "" H OH C,H, 
P-2565 
pressant action. This dissociation of central 
and peripheral actions has also been re-
ported in mice, rats, and dogs. In cats, the 
agent produces sedation and depletion of 
norepinephrine from sympathetic ganglia as 
well as the hypothalamus. 271 In contrast, in 
the rabbit, there is evidence for selective 
depletion of norepinephrine in sympathetic 
ganglia by this compound. Inasmuch as 
dogs show no sedative effect from this 
agent, it would appear that man behaves 
more like the dog and rabbit than the cat. 
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A similar dissociation of peripheral and 
central depletion of norepinephrine and 
serotonin has been reported for syrosingo-
pine in the rabbit and dog by Orlans, 
Finger, and Brodie. "RS Doses of syrosingo-
pine which do not sedate these species 
have peripheral cardiovascular hypoten-
sive effects. Similar differential effects have 
been observed with small doses of reser-
pine by Carlsson and co-workers,56 but 
over a narrower dose range than syrosingo-
pine. In man, syrosingopine can lower 
blood pressure in doses relatively free of 
central effects.eo 
An interesting chemical development is 
the synthesis of reserpine analogues, of 
which tetrabenazine is the best known. 
The compound is much less potent and 
shorter acting than reserpine. Although 
its therapeutic use appears quite limited, 
it is of considerable theoretic importance 
and serves as a prototype of many newer 
derivatives. Quinn, Shore, and Brodie2GO 
showed in rabbits that the drug has a more 
selective effect centrally. The agent appears 
to depress brain norepinephrine and sero-
tonin, having little effect peripherally. The 
agent appears to depress brain norepineph-
rine more than serotonin levels, although 
the sedative effect seems to be correlated 
with the latter. After intravenous adminis-
tration, the compound is rapidly and almost 
completely metabolized. In contrast to re-
serpine, the duration of action of tetra-
benazine is limited to the short time appre-
ciable quantities are in the body. Inasmuch 
as animals given tetrabenazine before re-
serpine act as though they received only 
tetrabenazine, Quinn, Shore, and Brodie 
concluded that both drugs compete for 
the same receptor sites. In man, the drug 
is said to produce no diarrhea, in contrast 
to reserpine. 317 Both compounds are said 
to have similar central nervous system ef-
fects, although undesirable central effects 
of tetrabenazine limit its clinical usefulness. 
Several other benzoquinolizines are of 
theoretic interest. Pletscher and associ-
ates251, 252 determined the effects of RO 
4-1284 and RO 4-1398 on the brain levels 
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of serotonin and norepinephrine in mice. 
They found that both compounds depressed 
brain serotonin equally but had differential 
effects on brain norepinephrine. Brain sero-
tonin was maximally depressed at 1 hour 
and recovered in about 6 hours after each 
compound. On the other hand, brain nor-
epinephrine was much more depressed by 
Ro 4-1284 than after Ro 4-1398; Similarly, 
the degree of overt depression was greater 
after Ro 4-1284 than Ro 4-1398. They con-
cluded that the sedative effects induced 
by these agents correlated better with the 
depression of brain norepinephrine rather 
than serotonin. Quinn, Shore, and Brodie,260 
however, were not able to confirm this in 
mice as well as rabbits and concluded in-
stead that the sedative effects more easily 
correlate with depression of brain serotonin 
than of norepinephrine. 
Finger, Weisman, and Tretter96 have 
pointed out that there may be no corre-
lation between depression of conditioned 
behavior and levels of the central amines, 
serotonin, and norepinephrine with several 
other substituted benzoquinolizines which 
they studied. One compound, P-2647 
(benzquinamide ), was much more effec-
tive in depressing avoidance behavior and 
produced negligible changes in the levels 
of brain amines as well as any overt seda-
tion, ptosis, lacrimation, and salivation. On 
the other hand, its hydroxy derivative, 
P-2565, was less effective in depressing 
avoidance behavior and yet had greater 
effects in lowering brain amine levels. This 
compound produced overt sedation, ptosis, 
etc. If these results are confirmed, it would 
appear that ability to depress avoidance 
behavior and depletion of serotonin and 
norepinephrine are unrelated phenomena. 
Some of these interesting compounds are 
currently being evaluated in man as poten-
tial therapeutic agents. The relatively 
quicker onset and shorter duration of ac-
tion makes them more desirable in some 
respects than reserpine. Furthermore, the 
possibility that a central effect (depression 
of conditioned behavior) may occur with-
out any appreciable depletion of brain 
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amines suggests that the latter may be 
more related to untoward effects than to 
the primary pharmacologic action of the 
drug. Only more research, both basic as 
well as clinical, will provide the necessary 
answers. 
Central and autonomic nervous system 
effects. The marked behavioral alterations 
produced by reserpine and related com-
pounds include mild depression of the 
central nervous system, a decrease in 
sympathetic activity and an increase in 
parasympathetic effects. In animals, the 
behavioral alterations may be dramatic. 
Hostile and aggressive monkeys become 
tame and can be safely handled. Condi-
tioned avoidance and conditioned suppres-
sion behavior are depressed in all animal 
species tested. Human subjects receiving 
reserpine are more relaxed and tend to go 
to sleep more readily but are easily aroused 
even though large doses were ingested. The 
autonomic effects are clear-cut, with para-
sympathetic symptoms predominating. 
Thus, the pupils are miotic, pulse rate is 
decreased, blood pressure is lowered, gas-
trointestinal activity ( including secretion 
of gastric hydrochloric acid) increases, and 
temperature regulation is altered. The fall 
in blood pressure and heart rate occur even 
though serum sodium and chloride levels 
are unchanged. In fact, a slight increase in 
the levels of these ions may occur. There is 
an extensive literature on the effectiveness 
of these agents in reducing anxiety and 
maniacal states. Kline175, 176 reviewed some 
of the early reports of the use of the Rau-
wolfia alkaloids in psychiatric states and 
reported his own favorable results with it. 
The quieting effect on noisy wards was 
obvious, although the drug did not alter 
the basic schizophrenic process itself. 
Within a 1 year period, two major sym-
posia appeared on the behavioral and 
pharmacologic effects of these com-
pounds. 225 , 226 In the intervening years, 
clinical psychiatric interest in reserpine-like 
drugs has tended to decline as a result in 
part of the widespread use of the sub-
stituted phenothiazines. 41 Nevertheless, the 
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remarkable pharmacologic effects of the 
Rauwolfia alkaloids will always be of value 
in the selected psychiatriC or hypertenSive 
patient. 
Reserpine on psychologic tests in man 
does appear to possess certain unique 
properties. Lehmann and Csank200 com-
pared the effects of single oral doses of 
reserpine (2 mg.), chlorpromazine (100 to 
150 mg.), proclorperazine (30 to 60 mg.), 
secobarbital (100 to 200 mg.), D-ampheta-
mine (12.5 to 15 mg.), and caffeine citrate 
(600 to 900 mg.) on various psychologic 
tests in healthy human volunteers. Nine 
different psychologic tests were used, in-
cluding visual function, tapping speed, re-
action time, hand steadiness, learning ca-
pacity, and recall. Reserpine significantly 
increased afterimage sensitivity in contrast 
to chlorpromazine, proclorperazine, and 
secobarbital, which Significantly decreased 
this function. Chlorpromazine and seco-
barbital also caused a significant decrease 
of flicker fusion. Proclorperazine also 
depressed afterimage sensitivity, but un-
expectedly, it was a more powerful stim-
ulant of psychomotor performance than 
D-amphetamine or caffeine. It caused a 
marked decrease in reaction time and sig-
nificant improvement in hand steadiness, 
digit span, digit symbol, and cancellation 
tests. Lehmann and Csank pointed out that 
each drug has its own spectrum of psy-
chologic activity. The critical flicker fusion 
and afterimage disappearance level tests 
were especially sensitive to the various 
drugs tested as well as to other clas~es of 
psychotropic drugs such as the hallucino-
gens, including lysergic acid diethylamide 
and mescaline, which raised the critical 
flicker fusion frequency and the afterimage 
disappearance level. Another psychologiC 
study in which reserpine and chlorproma-
zine were compared with somewhat similar 
results was that by Watt and Crookes.323 
Reserpine in doses of 2 to 30 mg. per day 
to manic females caused an impairment in 
visual input as measured by the flicker 
fusion threshold, hue discrimination, and 
duration of a negative afterimage. There 
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was no consistent effect on tests of motor 
or association functions. Chlorpromazine, 
in contrast, in doses of 300 mg. per day 
impaired both the flicker fusion and motor 
performance. 
Depending upon the dose and duration 
of therapy, reserpine may show negligi-
ble or definite electroencephalographic 
changes. 7G Monroe and colleagues229 com-
pared the effects of reserpine, chlorproma-
zine, and amobarbital on various cortical 
and subcortical sites in psychiatric patients 
with chronic implanted brain electrodes. 
Reserpine in doses of 5 to 10 mg. intra-
venously produced relaxation within 15 
minutes after injection. The patients were 
quiet and appeared to be asleep. If they 
were approached, they would easily arouse. 
Sometimes they would say they were 
sleepy, but often they would not. The 
electroencephalographic recordings were 
not markedly altered. Combinations of 
reserpine and amobarbital produced deeper 
behavioral depression than either drug 
alone, although the electroencephalo-
graphic changes resembled those after 
amobarbital alone. Like reserpine, chlor-
promazine in doses of 50 to 100 mg. given 
intravenously to 4 human subjects with 
implanted electrodes produced no dis-
tinctive electroencephalographic changes, 
except that the patients showed a more re-
laxed record with short bursts of drowsi-
ness and occasional light sleep, during 
which the subjects appeared to be sleeping. 
Electroencephalographic and behavorial 
arousal was easily produced. The electro-
encephalographic effects which occur after 
chronic administration of chlorpromazine 
and other phenothiazines were also seen 
with chronic administration of reserpine in 
schizophrenics.H2 Generalized dysrhythmia 
and focal slowing were most commonly 
observed. 
The cardiovascular effects of reserpine in 
man have been described in detail in the 
first major symposium on this subject. 225 In 
general, the hypotensive actions of this and 
related Rauwolfia alkaloids are mild, con-
sisting of a slight but definite decrease of 
TranqUilizing drugs 635 
systolic as well as diastolic blood pressure. 
Intravenous infusions of 40 to 80 f-tg per 
kilogram of reserpine in hypertensive pa-
tients reduced the mean arterial blood 
pressure within 4 hours. The drop in pres-
sure was usually accompanied by nasal 
congestion, bradycardia, postural hypoten-
sion, and a feeling of relaxation. In the 
majority of patients, the blood pressure 
increased within 24 hours, but in a few, 
the blood pressure remained at normoten-
sive levels for 2 to 3 days after the infusion. 
Even in such relatively large doses as 5 mg. 
intramuscularly, reserpine usually produces 
a decrease in mean arterial pressure within 
20 minutes. Very large doses of 10 mg. pro-
duce an initial increase in blood pressure 
in some psychotic patients. It is not known 
to what extent the vehicle used for reser-
pine contributes to this response. (> 
The initial hypertensive phase is espe-
cially prominent with large toxic doses of 
reserpine in the dog.s4 Presumably, this is 
related to massive catecholamine release. 
In man in the usual therapeutic doses of 
reserpine, an initial pressor response is not 
seen because of compensatory mechanisms 
sufficient to handle the released catechol-
amines. 
Winsor332 studied the pharmacologic ef-
fects of reserpine on various tests in man. 
In 5 patients studied before and 1 month 
after reserpine administered daily in doses 
of 0.25 to 0.50 mg., the galvanic skin re-
sponse to inspiration was not significantly 
inhibited. Vasoconstriction of the digit to 
inspiration or pain induced by an electric 
shock, however, was definitely reduced, 
espeCially with oral doses of 2.8 mg. for as 
little as 3 days. Small doses of reserpine 
(0.25 to 0.50 mg.) daily for 30 days failed 
to inhibit the blood pressure or pulse rate 
increase resulting from placing the hand in 
ice water (cold pressor test). Larger doses 
were not apparently tried. This would be 
particularly important since one would ex-
pect the response to be depressed with ade-
quate peripheral adrenergic nerve catechol-
OJ. C. Saunders: Personal communication, 1956. 
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amine depletion (see section on mechanism 
of action). 
Endocrine effects. Gaunt and col-
leagues108 studied the effects of reserpine 
on the endocrine system of the rat. Numer-
ous effects were found which were related 
to stress such as the release of ACTH and 
possibly antidiuretic hormone. In the inter-
vening years, evidence has accumulated 
that reserpine may inhibit estrus and men-
struati~n/4 modify the uterine decidual re-
sponse73 altering fertility and block the 
release of pituitary gonadotropin. 16. 17 
ACTH release may be stimulated or de-
pressed and lactogenic hormone release 
enhanced (see Gaunt, Chart, and Renzi107 ). 
Egdahl, Richards, and Hume88 have 
noted that acute administration of large 
doses of reserpine (5 mg.) intravenously 
to dogs caused a marked increase in ad-
renal 17-hydroxycorticosteroid output. The 
response was delayed, with a peak occur-
ring between 112 and 3 hours after drug 
injection. These effects are compatible with 
large intravenous doses of ACTH, though 
comparatively much delayed. Harwood 
and Mason128 compared the acute effects 
(zero to 4 hours) of varying doses of reser-
pine, chlorpromazine, and pentobarbital on 
the plasma levels of 17-hydroxycorticoster-
oids in the monkey. Reserpine in small 
doses caused an elevation in 17-hydroxy-
corticosteroids at 1 and 2 hours after injec-
tion which tended to return toward control 
levels at 4 hours. Large doses of reserpine 
caused an increasing elevation of plasma 
levels of these steroids to 4 hours. In low 
doses, chlorpromazine caused an elevation 
in plasma levels of 17-hydroxy corti coste-
roids, while in large doses it produced a 
fall. Reserpine was more potent than chlor-
promazine in elevating the plasma levels of 
17 -hydroxycorticosteroids. In anesthetizing 
doses, pentobarbital depressed plasma 
levels of these steroids. Using the 17-hy-
droxycorticosteroid response to ACTH as a 
reference, it appeared that reserpine pro-
duced the maximal stimulation of the ad-
renal cortex. It is of interest that Tui, Riley, 
and Orr,310 using schizophrenic patients, 
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also found an elevation in the 17-hydroxy-
corticosteroid levels in response to reser-
pine and a depression in response to chlor-
promazine. Brodie and colleagues43 studied 
the actions of single doses of reserpine 
given to rats on various indices of pitui-
tary-adrenocortical activity. Reserpine in 
doses which produced profound sedation 
and depletion of brain amines caused a 
decrease in adrenal ascorbic acid and ele-
vated levels of plasma corticosterone and 
liver tryptophan peroxidase. Plasma free 
fatty acids at first diminished, then in-
creased. Adrenal weight increased 40 per 
cent in 24 hours. The pharmacologically 
inert stereoisomers of reserpine had no 
effect upon the brain amines or pituitary-
adrenal activity. The endocrinologiC altera-
tions induced by reserpine did not occur 
in hypophysectomized or adrenalectomized 
animals even though sedation and deple-
tion of brain amines were observed. These 
findings correlate with previous reports 
that ACTH levels in the pituitary are re-
duced after reserpine. 
Croxatto and Barnafi showed that reser-
pine administered chronically to normal 
rats decreased urine volume and sodium 
output. Paradoxically, the blood of these 
rats showed very little antidiuretic activity. 
Reserpine administration to rats given a 
water load produced an immediate anti-
diuretic effect. Similar findings have been 
reported by Gaunt and co-workers108 and 
Meier, Briini, and Tripod. 221 
Mechanisms of action. The ability of 
reserpine and its related sedative alkaloids 
and synthetic derivatives to release various 
amines from the brain and other peripheral 
sites has resulted in considerable specula-
tion that this accounts for its mechanism of 
action. Brodie and associates42 , 44-48, 136. 153. 
254, 255, 286, 288 have emphaSized the impor-
tance of serotonin release, while Holtzbaur 
and Vogt,147,234 Paasonen and Krayer,239 
Carlsson and colleagues,56 and others have 
emphasized depletion of catecholamines, 
including dopamine, norepinephrine, and 
epinephrine. Waalkes and Weissbach319 
have shown that reserpine releases hista-
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mine in addition to serotonin from rabbit 
platelets in vivo. The rat mast cell appar-
ently acts differently, for Bhattacharya and 
Lewis33 have shown that reserpine does not 
disrupt mast cells and specifically releases 
their serotonin without affecting histamine 
content. In contrast, the compound 48/80 
disrupts mast cells, releasing both histamine 
and serotonin. Waalkes, Coburn, and 
Terry318 have elaborated on their earlier 
observations and have shown that reserpine 
liberates serotonin readily from the whole 
blood, lung, intestine, and brain of both 
. guinea pigs and rabbits. Reserpine, how-
ever, liberates histamine readily only from 
the lung of guinea pigs and the blood, 
lung, and intestine of the rabbit. There is 
no decrease of histamine in the guinea pig 
brain, while the decrease in rabbit brain 
histamine was not considered Significant. 
Others have been able to confirm the 
observation that reserpine lowers histamine 
levels in rabbit blood but not in other rab-
bit tissues and have suggested that sero-
tonin released by reserpine may be respon-
sible for the histamine release from rabbit 
platelets. Haverback and coauthors130, 131 
have shown that serotonin and histamine 
have differential effects on gastric secretion. 
Serotonin decreases gastric secretion in the 
Heidenhane pouch. 5-Hydroxytryptophan 
decreases spontaneous gastric secretion but 
does not block the gastric responses to 
reserpine or histamine. I t is still unclear 
whether serotonin release of histamine 
would account for these phenomena. Ap-
parently, the effect of reserpine on gastric 
secretion is peripherally mediated inas-
much as intraventricular injection of reser-
pine does not increase gastric acidity while 
peripheral injections do. 
Sulser and Brodie293 have posed the 
question, "Is reserpine tranquilization 
linked to a change in brain serotonin or 
norepinephrine?" They have concluded 
that it is related to the former. Their argu-
ments follow: 
Although Karki and Paasonen concluded that 
raunescine caused sedation in rats and lowered 
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brain norepinephrine but not serotonin, the Na-
tional Institutes of Health group has evidence that 
both amines are lowered by this alkaloid. 
Although Pletscher and associates offered evi-
dence that the sedative action of 2-benzoquinoli-
zine derivatives in mice was associated with loss 
of brain norepinephrine, the National Institutes of 
Health workers found that 20 minutes after injec-
tion, brain serotonin levels were also depressed. 
They argued that serotonin is synthesized rapidly, 
and this accounts for the higher serotonin levels 
found 1 hour later. 
The findings of Sheppard and Zimmerman of 
an elevated norepinephrine level in guinea pig 
brain following reserpine was discounted on the 
basis of lack of evidence that their fiuorometric 
methods were specific. The National Institutes of 
Health group concluded that at no time did nor-
epinephrine levels in brain or heart increase after 
reserpine administration. Brain levels of both nor-
epinephrine and serotonin declined at the same 
rate and to the same extent. 
The evidence for a dissociation between nor-
epinephrine and serotonin is provided by the data 
of Garattini and Valzelli that reserpine adminis-
tration to rats exposed to cold caused no sedation 
and no decline in brain serotonin. The National 
Institutes of Health workers have shown that un-
der these circumstances, norepinephrine levels 
decrease, and in confirmation of the Italian work-
ers, they showed no change in brain serotonin or 
gross behavior. Hypophysectomized rats, however, 
did show sedation and a fall in brain levels of 
both amines. Before this question can adequately 
be settled, more precise psychologic measures of 
sedation or tranquilization need to be used in con-
nection with the chemical data. It is very difficult 
to determine in rats exposed to cold whether the 
animals are sedated or not. 
SU-5171 (dimethylaminobenzoyl methylreser-
pate) releases little brain serotonin despite a 
marked fall in brain norepinephrine in rabbits. 
These animals show no evidence of sedation. 
Norepinephrine loss centrally is not accom-
panied by decreased peripheral sympathetic ac-
tivity. Furthermore, various nonsedative drugs 
may alter central norepinephrine levels. 
Brodie and associates45 , 46, 48 suggest that 
although total amine levels are lowered, 
free amine levels are not necessarily, and 
that the effects on the central nervous sys-
tem depend upon the levels of free amines 
at receptor sites. Inasmuch as they claim 
there is a rapid syntheSis of serotonin as 
compared to norepinephrine, the effects of 
free serotonin may predominate. Admit-
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tedly, brain norepinephrine levels may fall 
in a variety of drug-induced states such as 
morphine mania in cats as shown by Vogt. 
Inasmuch as reserpine depletes the brain 
of dopamine and as dopamine is a precur-
sor for norepinephrine and epinephrine, 
the synthesis of these latter substances 
must be interfered with. It appears that 
probably both serotonin and catecholamine 
depletion may be related to the action of 
reserpine. The possibility that other mech-
anisms may be more important should also 
be kept in mind. Transport mechanisms in 
addition to binding sites may be involved. 
Hughes and Brodie'52 have shown that the 
entry of serotonin into guinea pig platelets 
in vivo is retarded by reserpine. Evidence 
was obtained that this effect was produced 
via an inhibition of an active transport sys-
tem. A similar depressant effect of reser-
pine was noted on the uptake of norepi-
nephrine and epinephrine by platelets. An 
interesting effect of reserpine has been 
described by von Euler and Lishajk094 in 
inhibiting the spontaneous release of nor-
epinephrine from isolated nerve granules 
in vitro. The rate of release was greatly 
enhanced by DOPA. This observation in-
dicates that the releasing action of reser-
pine requires an intact nerve cell and that 
the spontaneous release from isolated nerve 
granules is actually inhibited. 
There is good evidence that in man, 
reserpine may deplete blood platelets of 
serotonin. Green, Paasonen, and Giarman 118 
found that blood serotonin values were de-
pressed for 3 weeks after a 3 week course 
of 1.5 to 3 mg. of reserpine given daily to 
chronic schizophrenics. Hardisty, Ingram, 
and Stacey'26 and Haverback and associ-
ates'29 have also noted that reserpine de-
pletes human platelets of serotonin in vivo 
for as long as 3 weeks following 1 mg. of 
reserpine given intramuscularly. More re-
cently, Freedman and Benton'02 studied 
the persisting effects of reserpine in man on 
blood serotonin levels and pupil size in a 
group of chronic schizophrenic women. 
After an oral dose of 10 mg. of reserpine, 
most of the patients became quite ill. 
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There was vomiting, diarrhea, insomnia, 
weakness, lassitude, drowsiness, depression, 
and psychosomatic irritability. These ef-
fects began about 2 hours after the drug 
was given and lasted about 24 hours. The 
blood serotonin levels fell and continued to 
be low after two 10 mg. oral doses of reser-
pine for up to 5 weeks. Miosis was present 
for 7 days after reserpine therapy. These 
authors concluded that man is exceedingly 
sensitive to these effects of reserpine. They 
pointed out that the serotonin-depleting 
effect on platelets cannot be due. only to 
the platelets present at the time of drug 
administration since the life of human 
platelets is only 8 to 14 days. They suggest 
a reserpine action on megakaryocytes or 
their precursors and a sensitizing action on 
amines in that the first dose of reserpine 
sensitizes to depletion by a second dose. 
It is well known that the 5-hydroxyin-
dole acetic acid content of the urine re-
flects over-all body serotonin levels. Inas-
much as larger amounts of serotonin are 
present in intestine and blood than in 
brain, the former tissues contribute most to 
urinary levels of 5-hydroxyindole acetic 
acid. Since this is the major end product 
of serotonin metabolism, nevertheless, it 
should be affected by reserpine administra-
tion. Valcourt314 was able to show that 2 
mg. of reserpine given twice daily to psy-
chiatric patients caused an increase in uri-
nary 5-hydroxyindole acetic acid levels. 
After the first day of treatment, the urinary 
levels were reduced to control or less. 
Brune and Hinwich50, 51 determined the 
urinary excretion of 5-hydroxyindole acetic 
acid in psychiatric patients given 2 mg. of 
reserpine twice daily for 14 days, followed 
by 10 mg. of isocarboxazid three times 
daily in addition and vice versa. An ag-
gravation of psychotic symptoms was re-
flected by an increase in 5-hydroxyindole 
acetic acid in the urine. The levels fell 
slightly during isocarboxazid therapy but 
rose during the combined reserpine-iso-
carboxazid period. The total indole-3-acetic 
acid tended to parallel the alterations in 5-
hydroxyindole acetic acid. 
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Evidence is accumulating that reserpine 
may not be acting only through its effects 
on brain amines. Gal, Drewes, and Barra-
cloughlOG maintained rats on a tryptophan-
dencient diet. The diet-dencient animals 
had 70 per cent lower brain levels of sero-
tonin than normal controls. Norepinephrine 
brain levels were normal. In tryptophan-
dencient rats, reserpine caused a markedly 
prolonged depletion of serotonin while 
norepinephrine levels returned to normal 
much sooner. Even though there was little 
serotonin in the brain, a second injection 
of reserpine produced sedation. These in-
vestigators concluded that in the rat, reser-
pine effects do not require the presence of 
serotonin in the brain. 
Although catecholamine and serotonin 
levels are depleted from various tissues in-
cluding brain, the acetylcholine levels of 
the brain usually rise. 215 This occurs in 
most structures, except in the hippocampus. 
The latter is a site where reserpine may 
cause stimulation. It is unclear to what 
extent these changes are related to the 
sedative effects of reserpine. Malhotra and 
Das214 studied further the effects of reser-
pine on the acetylcholine content of the 
heart, ileum, and hypothalamus of the dog. 
Reserpine increased the acetylcholine levels 
in all tissues studied. The increase in pe-
ripheral tissues was greater than in the 
hypothalamus. They concluded that the 
bradycardia and purgative effects of reser-
pine may be related to peripheral increases 
in acetylcholine in the tissues involved. 
The observations that reserpine prolongs 
diphosphopyridine nucleotide levels further 
complicates the picture. Burton and col-
leagues55 have observed that reserpine and 
deserpidine (as well as chlorpromazine and 
promazine but not meprobamate, pento-
barbital, or ethanol) prolong the high di-
phosphopyridine nucleotide levels in rat 
liver induced by nicotinamide. Randall, 
Atkinson, and Iliev261 have shown that 
iproniazid treatment did not modify the 
reserpine prolongation of diphosphopyri-
dine nucleotide levels of nicotinamide in 
contrast to its effects in blocking reserpine 
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depletion of serotonin, catecholamines, and 
overt depression. Much evidence has accu-
mulated that reserpine and chlorpromazine 
act differently with regard to catechol-
amine and serotonin levels in the brain. 
Although both reserpine and the pheno-
thiazines prolong hexobarbital sleeping 
time in mice, they apparently act differ-
ently in this regard as well. Monosodium 
glutamate further prolongs reserpine en-
hancement of hexobarbital sleeping time 
but not that of proclorperazine. l8l 
Further evidence of the complexity of 
reserpine pharmacology is its effect on 
brain y-aminobutyric acid levels. Balzer, 
Holtz, and Palm13 have shown that reser-
pine causes a long-lasting depletion of 
y-aminobutyric acid in the brains of mice, 
which correlates with the decrease in elec-
troshock seizure threshold produced by 
reserpine. Iproniazid pretreatment prevents 
the depletion of y-aminobutyric acid and 
the decrease in electroshock threshold. 
Similar results have ~een obtained by Palm, 
Balzer, and Holtz. 240, 241 The authors felt 
the decrease in brain y-aminobutyric acid 
was not the actual cause of the lowering 
effect on electroshock threshold but only 
an indicator of the interference of reserpine 
with glutamic aCid-y-aminobutyric acid 
metabolism in the brain. To further com-
plicate the picture, MacLean210 has ob-
served that after reserpine, there is a de-
crease in ·the uptake of radioactive methio-
nine in the hippocampus. 
Not all of the actions of reserpine on the 
brain are specinc. Some appear to be re-
lated to simple central nervous system de-
pression. For example, Mathe and Kassay219 
observed that reserpine raised the brain 
glycogen levels of rats on both acute and 
chronic administration. Lactic and pyruvic 
acid levels were also elevated. Other cen-
tral nervous system depressants such as 
chlorpromazine and meprobamate had 
somewhat similar effects, while electro-
shock or pipradol caused an immediate de-
crease. These effects, therefore, appear to 
be related to utilization of substrate by the 
brain. 
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Metabolic fate. Bein23 and MaynerF20 
have reviewed the literature on the meta-
bolic fate of reserpine. Both agree that 
there is little correlation between the levels 
of reserpine and its known metabolites in 
the brain and the duration of its pharma-
cologic effects. The notion that reserpine is 
"a hit and run drug" therefore may be valid 
in that the compound causes a central ac-
tion (such as depletion of brain amines) 
which persists beyond the presence of the 
drug in the body. Nevertheless, it cannot 
be accepted that this is the ultimate mech-
anism of action of reserpine until the dis-
tribution and fate of all reserpine metabo-
lites are known. Theoretically, the most 
likely possibilities for metabolic breakdown 
would be hydrolysis of the ester linkage 
and demethylation. There is very good evi-
dence both in vitro and in vivo that hy-
drolysis takes place with methyl reserpate 
and trimethoxybenzoate as the breakdown 
products. Species differences as well as the 
route of administration determine the per-
centage change caused by hydrolysis. For 
example, on oral administration of reser-
pine to rats, 22 per cent appears in the 
urine and 45 per cent in the feces as methyl 
reserpate. The same dose of reserpine 
given parenterally results in a urinary 
level of methyl reserpate of less than 1 per 
cent of the dose. In other species such as 
the dog and monkey, regardless of the 
route of administration, only small amounts 
of methyl reserpate are found in the ex-
creta and tissues. In addition to methyl 
reserpate, reserpic acid, syringic acid, and 
syringoyl methyl reserpate have been re-
covered after reserpine administration. The 
other product of simple hydrolysis, 3,4,5-
trimethoxybenzoic acid, has also been re-
covered from urine. Maynert does not feel 
that simple hydrolysis is the primary 
mechanism of reserpine detoxification. 
O-Demethylation of reserpine has also been 
demonstrated. Animals injected with the 
C14-labeled drug in the 4-methyl group of 
the trimethoxybenzoyl portion of the mole-
cule exhale 24 per cent of the radioactivity 
in the breath in a 6 hour period. O-De-
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methylation derivatives of reserpine (syrin-
goyl methyl reserpate and syringic acid) 
have also been detected in rat tissues. After 
intravenous injection, reserpine appears to 
be rapidly removed from the blood stream. 
For example, 2 minutes after intravenous 
injection, only 0.3 per cent remains in the 
blood. The rest is concentrated in various 
tissues, especially those with high lipid 
content. Inasmuch as blood flow to neutral 
fat is rather low, these sites reach peak 
concentrations in about 4 to 6 hours. Of 
considerable interest, reserpine-induced se-
dation does not coincide with its peak con-
centration in the brain as a whole or in its 
separate parts. Sheppard and associates284 
also used randomly tritum-Iabeled reser-
pine in order to study its distribution. The 
results obtained were similar to those previ-
ously reported using C14-labeled reserpine 
in the trimethoxybenzoic acid portion of 
the molecule. 283 The conclusion that the 
intensity of central pharmacologic effects 
of reserpine bears no relation to its concen-
tration in brain was further supported by 
this study. The authors also pointed out 
that the lowering of serotonin and catechol-
amine levels in the brain, as reported by 
others, also is poorly correlated with the 
gross observable effects of reserpine. One 
of the major criticisms of most chemical 
studies is that the chemical events in the 
brain are correlated with gross observation 
of the animals rather than specific psy-
chologic behavioral tests. It is obvious that 
peripheral symptoms may influence an in-
vestigator in assuming the animal is se-
dated. 
Reserpine apparently can cross the pla-
cental barrier. Infants of mothers who 
received the agent prior to delivery may 
show severe toxic symptoms and nasal dis-
charge and occasionally may die from 
anoxic complications. 02, 2H6 
Plummer, Sheppard, and Schulert256 have 
summarized their findings on the metabo-
lism of reserpine. Their conclusions are in 
agreement with what has been reported 
previously, in that the metabolites of reser-
pine include trimethoxybenzoate, methyl 
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reserpate, reserpic acid, syringomethyl re-
serpate, syringic acid, and carbon dioxide. 
There appears to be no relation between 
the sensitivity of any given species and the 
pattern of metabolism of reserpine. The 
rate of uptake of reserpine by the brain 
resembles that of other tissues except neu-
tral fat. There does not appear to be a 
differential distribution of reserpine in 
different brain areas. It is of interest that 
Plummer, Sheppard, and Schulert were 
able by very sensitive radioactive labeling 
procedures to show the presence of reser-
pine in the brain for at least 48 hours after 
injection of small pharmacologically active 
doses. This latter observation is of crucial 
importance and raises some doubts on the 
concept of a hit and run action of reserpine. 
Again, more precise behavioral correlations 
with chemical data will provide evidence 
necessary to accept or reject this concept. 
Adverse effects. Hollister141 has reviewed 
the adverse effects of the Rauwolfia alka-
loids. Several categories have been de-
scribed,177 which comprise behavioral 
effects including depression and suicide, 
extrapyramidal symptoms, autonomic sys-
tem effects, and allergic and endocrine 
effects. Depression is both the most com-
mon and the most serious behavioral effeCt 
which may lead to suicide. Occasionally, 
adverse psychotic symptoms may be 
evoked. The extrapyramidal symptoms usu-
ally produced by reserpine are those of a 
classic type of parkinsonism. In contrast to 
the phenothiazines, the dystonias are very 
rare. Rare choreoathetotic and cerebellar 
syndromes have been seen. Reserpine has 
been reported to lower the convulsive 
threshold in manl76 , 235 as well as to control 
seizures. 190 
Autonomic system effects include in-
creased parasympathetic and decreased 
sympathetic effects. These consist of brady-
cardia, flushing, salivation, diarrhea, nasal 
congestion, hypotension and syncope, and 
activation of a peptic ulcer or acute gastric 
erosions. Interestingly, the Rauwolfia al-
kaloids do not produce many allergic phe-
nomena. Both thrombocytopenic and non-
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thrombocytopenic purpura have been ob-
served rarely. Allergic disorders may be ag-
gravated by these agents. Patients taking 
the Rauwolfia drugs may gain weight, part 
of which is fluid; frank edema may occur. 
These agents may act to release antidiuretic 
hormone. 
The endocrinologic actions of reserpine 
may be marked (see section on endocrines). 
In men, feminizing effects may occur, with 
loss of libido and impotence. Reserpine 
may antagonize the effects of thyroxine. In 
fact, it has been used therapeutically in 
selected patients with thyrotoxicosis. 
Meprobamate 
Meprobamate is a 2-methyl-2-n-propyl-l, 
3-propanediol dicarbamate. It was synthe-
sized by Ludwig and Piech in 1950. Its 
structure is as follows: 
o CH3 0 
II I II 
H,N-C-OCH2-C-CH,OC--NH, 
I 
CH,CH,CH3 
It is a white, bitter powder with a mild 
characteristic odor. It is freely soluble in 
alcohol and various organic solvents but 
only slightly soluble in water. 
The principal pharmacologic effect of 
meprobamate is depression of the central 
nervous system. Berger27 described mepro-
bamate in animals as a mephenesin-like 
drug producing skeletal muscle relaxation, 
protection against pentylenetetrazol, strych~ 
nine, and the tonic phase of electroshock 
seizures, prolongation of barbiturate anes-
thesia, and a sedative effect which causes 
monkeys to be handled more easily. Since 
then, much has been written describing the 
effects of this agent in animals and man. 
To say the least, meprobamate is a contro-
versial drug. Its widespread clinical ac-
ceptance is probably due to a very complex 
set of circumstances, including a desire on 
the part of many phYSicians for a nonbar-
biturate sedative, efficient drug advertising, 
and the apparent effectiveness of mepro-
bamate in relieving anxiety without pro-
ducing too much drowsiness. 
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Antianxiety effects. Laties and Weiss197 
have reviewed the available literature on 
the effectiveness of meprobamate in the 
treatment of anxiety. The large percentage 
of published uncontrolled studies with this 
agent led them to the conclusion that no 
good evidence exists on the unique superi-
ority of meprobamate as an antianxiety 
agent. The reader is referred to their criti-
cal survey of the literature to 1958 and 
their analysis of the various errors in clini-
cal design of experiments. Even though 
many investigators thought they were con-
ducting controlled experiments, in reality 
they were not. Their review is a striking 
testimonial to the insufficiency of all of us 
as members of the medical profession in 
knowledge of proper clinical research 
deSign. 
Even if one accepts the statement that 
meprobamate is an effective antianxiety 
agent, it still is pertinent to ask if it is phar-
macologically unique in this regard. Laties 
and Weiss concluded that there was no 
good evidence available to suggest it was 
better than a barbiturate. In fact, there was 
some evidence that it might not be as good. 
Since then, several other studies have been 
published which bear on this question. The 
study of Moyer and associates232 in which 
meprobamate (800 to 2,400 mg. per day), 
phenaglycodol (600 to 1,600 mg. per day), 
and benactyzine and its related derivative 
(3 to 8 mg.) were compared to phenobar-
bital (120 mg. per day) and a placebo does 
not indicate any unique over-all effective-
ness of meprobamate in relieving anxiety 
and tension in psychoneurotics. Even when 
meprobamate was compared to these rela-
tively low. doses of phenobarbital, it was 
noted that patients who responded to 
phenobarbital also responded to mepro-
bamate. There was no correlation between 
severity of the symptoms and responsive-
ness to both agents. Similarly, there was no 
significant difference in the degree of re-
sponse in patients reacting favorably to 
both drugs. Meprobamate was the most 
effective of the four new experimental 
drugs tested (excluding phenobarbital), 
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but subjective improvement was better 
than objective improvement. Objectively, 
the response to all four agents was com-
parable. The authors pointed out that al-
though meprobamate was effective in ap-
proXimately 25 per cent more patients than 
phenobarbital, the dosage of the latter drug 
was rather low. They suggested that larger 
doses probably would have produced an 
increase in response comparable to the four 
other experimental drugs. Another com-
parative drug study is that of Rickels and 
co-workers.265 These investigators deter-
mined the effects of amobarbital sodium 
(30 mg.), meprobamate (400 mg.), pro-
clorperazine (5 mg.), and a placebo given 
four times per day for 2 weeks in a random 
order to psychoneurotic outpatients with 
predominant symptoms of anxiety, tension, 
and mild depression in the absence of evi-
dent organic disease. A series of psycho-
logiC and psychiatric improvement scales 
was used to evaluate the subjects. It was 
concluded that all four treatments signifi-
cantly influenced the patients during the 
first 2 weeks. Thereafter, only the three 
active drugs significantly gave better re-
sults. Therapy with meprobamate pro-
duced the most marked change toward 
improvement. It is regrettable that a larger 
dose of amobarbital was not used. Dickel 
and colleagues77 compared the effects of 
meprobamate (400 mg.), chlordiazepoxide 
(10 mg.), and phenobarbital (50 mg.) in 
a double blind, crossover fashion in 36 
working outpatients with presenting symp-
toms of anxiety. The drugs were given for 
2 weeks each on a schedule of three or four 
times daily. All of the patients were evalu-
ated on the basis of psychiatric interviews 
and about half on the degree of relaxation 
in response to faradic stimulation, ability to 
perform tasks, solve problems, etc. Mepro-
bamate was found to be most effective in 
reducing anxiety in the working patient, 
while chlordiazepoxide appeared more 
useful in more severe emotional disorders. 
In this study, phenobarbital, while useful 
in some cases, had the least over-all effec-
tiveness. 
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Soporific effects. Meprobamate appears 
to be effective in promoting sleep. La-
sagna193 compared a series of sleep-induc-
ing agents including a placebo (lactose), 
methyprylon (0.25 and 0.5 Gm.), mepro-
bamate (0.4 and 0.8 Gm.), pentobarbital 
(0.1 and 0.2 Gm.), secobarbital (0.1 and 
0.2 Gm.) and phenobarbital (0.1 and 0.2 
Gm.) on the promotion of sleep in patients 
with various chronic diseases. He con-
cluded that meprobamate has hypnotic 
properties resembling phenobarbital. The 
most satisfactory results in promoting sleep 
were obtained with 0.2 Gm. of secobarbital 
and pentobarbital. Batterman and coau-
thors21 compared phenobarbital (15 mg.), 
butabarbital ( 15 mg. ), acetylcarbromal 
(200 mg.), glutethimide (250 Gm.), me-
probamate (400 mg.), and proclorperazine 
(5 mg.) given three to four times daily to 
nervous outpatients for daytime sedation 
and nighttime hypnotic effects. Of these, 
butabarbital was the most satisfactory, 
while meprobamate was least satisfactory, 
especially as a daytime sedative. The au-
thors pOinted out that effectiveness for 
daytime sedation does not necessarily par-
allel effectiveness for nighttime hypnosis. 
For a single agent with both effects, buta-
barbital appeared to be the best. Rickels 
and associates,265 in comparing meproba-
mate (400 mg.) to amobarbital (30 mg.), 
proclorperazine (5 mg.), and a placebo 
given four times daily for 2 weeks to psy-
choneurotics, noted that although amobar-
bital produced more daytime drowsiness, 
meprobamate was most effective in reliev-
ing insomnia. The authors felt the beneficial 
effect could not be due to a primary seda-
tive (hypnotic) effect but might be due to 
skeletal muscle relaxation. 
Skeletal muscle relaxant effects. There 
appears to be some evidence that mepro-
bamate relaxes skeletal muscle tension in 
animals and man. 301 The critical question is 
whether this effect is due to a specific 
skeletal muscle relaxant action or to seda-
tion. Surprisingly, very few critical studies 
have been made in which several central 
nervous system depressants were compared 
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to meprobamate. Vuzuka315 studied the 
muscle relaxant effects of methocarbamol 
( 1,250 mg.), meprobamate (400 mg.), and 
zoxazolamine (500 mg.) given orally three 
or four times daily to a series of patients 
with neuromuscular disorders. He used 
clinical observations, photographic record-
ings, and electromyographic and myometric 
studies to evaluate the degree of skeletal 
muscle relaxation. The patients showed 
varied degrees of muscle spasticity, ankle 
clonus, and spasms. Meprobamate ap-
peared to be the most effective, methocar-
bamol second, and zoxazolamine least 
active in relieving spasticity. Nyquist, Co-
marr, and Bors237 compared meprobamate 
(800 mg.), phenobarbital (50 mg.), zox-
azolamine (500 mg.), and a placebo given 
orally three or four times daily to patients 
haVing spasticity associated with spinal 
cord injuries. After 7 days of treatment, all 
three agents were more effective than the 
placebo in having a relaxant effect on 
skeletal muscle. In these doses, meproba-
mate was more effective than phenobarbi-
tal, while zoxazolamine was least active. 
These investigators concluded that pheno-
barbital was a valuable substitute for 
meprobamate. Lamphier and Pine191 com-
pared meprobamate (400 to 800 mg.), 
emylcamate (200 to 400 mg.), and a pla-
cebo given usually three times daily for 2 
to 4 days to hospitalized patients and 1 to 
60 days to office patients with spastic mus-
cular disorders and psychosomatic symp-
toms. Both drugs were more effective than 
a placebo, but emylcamate was superior 
to meprobamate. 
A particularly important unpublished 
study 4 by Bayliss deserves special attention 
even though meprobamate itself was not 
studied. This investigator studied the ef-
fects of mephenesin, methocarbamol, zox-
azolamine, chlorzoxazone, chlormethazone, 
and secobarbital given acutely in adequate 
therapeutic doses on the electromyograms 
of paraplegic patients with muscle spasms 
and hypertonicity. He concluded that there 
os. M. Bayliss: Personal communication, 1961. 
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was no marked difference in effect of the 
skeletal muscle relaxants compared to seco-
barbital. 
Perlstein, Turner, and Elam247 compared 
the effects of chlorpromazine (25 to 50 mg. 
intravenously or intramuscularly), mepro-
bamate (400 mg. intramuscularly), pento-
barbital (200 mg. intramuscularly), and an 
experimental drug, MR 710 (900 mg. 
orally), in 7 patients with tetanus using 
clinical and electromyographic criteria. 
Chlorpromazine and pentobarbital reduced 
but did not eliminate the spontaneous elec-
tromyographic activity and the spasms trig-
gered by various stimuli. Both drugs, how-
ever, caused sleepiness to the point of 
coma. Meprobamate eliminated the spon-
taneous activity at rest and dramatically 
stopped the spas,ms produced by external 
stimuli. It did not prevent spasms induced 
by internal stimuli. MR 710 diminished the 
spontaneous activity at rest as well as the 
induced spasms. It was more soporific than 
meprobamate. Meprobamate had the least 
soporific effect. In a more recent study, 
Perlstein, Stein, and Elam246 continue to 
favor the use of meprobamate intramus-
cularly over chlorpromazine and the barbi-
turates in the treatment of tetanus. Difficult 
cases usually require multiple medications 
and other supportive therapy. 
As might be anticipated from animal 
studies, meprobamate has been found to 
control certain patients with petit mal and 
related epilepsies. Generally, meprobamate 
is ineffective in grand mal and, like other 
drugs used in petit mal, may sometimes 
aggravate grand mal attacks. Perlstein245 
considers meprobamate less effective than 
trimethadione but as effective as para-
methadione. Meprobamate has an advan-
tage over these agents in that it has fewer 
serious effects. 
Effects on various objective behavioral 
tests. Marquis and colleagues217 studied the 
effects of single doses of a lactose placebo 
(1,400 mg.), meprobamate (800 mg.), D-
amphetamine ( 15 mg. ), meprobamate 
(800 mg.) plus alcohol (2 ounces of 86 
proof whiskey), and a lactose placebo 
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(1,400 mg.) plus alcohol (2 ounces of 86 
proof whiskey) in a series of normal sub-
jects given various objective behavioral 
tests including reaction time, driving skill, 
steadiness, and visual performance using an 
Ortho-rater. Meprobamate had no signifi-
cant depressant effect, while alcohol did 
impair performance on some of the tests. 
Combinations of meprobamate and alcohol 
did not show any enhanced effect. Subse-
quent studies on the chronic administration 
of 1,600 mg. of meprobamate per day for 
3 to 4 weeks also showed that meproba-
mate alone had no adverse depressant ef-
fects.166.167 However, single doses of 800 
and 1,600 mg. of meprobamate were found 
by Kornetsky183 to produce a significant 
impairment of learning and reaction time 
in normal subjects tested on a multiple 
stimulus-response apparatus. Three pro-
cedures were used: simple motor behavior, 
choice reaction time, and learning. This 
investigator also studied the effects of 
phenobarbital (60 and 120 mg.), D-am-
phetamine (5 and 15 mg.), and a placebo. 
In contrast to the significantly impaired 
performance after meprobamate, the latter 
agents did not significantly alter motor co-
ordination, reaction time, or learning. The 
failure of D-amphetamine to facilitate per-
formance of normal nonfatigued subjects is 
in general agreement with other studies in 
the literature. 
Melander222 also studied the effects of 
meprobamate (400 mg.), placebo, and 
amobarbital (100 mg.) given in single doses 
on simulated automobile driving. There 
was no significant difference between me-
probamate and the placebo, while amobar-
bital did depress driving skill. It should be 
noted that the dosage of meprobamate was 
rather small compared to that of amobarbi-
tal. Loomis and West"°6 also studied the 
effects of a series of drugs on simulated 
driving skill. The agents used were com 
starch placebo (200 mg. ), secobarbital 
(100 mg.), chlorpromazine (50 mg.), me-
probamate (400 mg.), and phenaglycodol 
(300 mg.) given in several doses under 
controlled conditions including a light 
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breakfast and a standard lunch. All drugs 
except the placebo and phenaglycodol pro-
duced a Significant impainnent of perform-
ance on the test apparatus. Secobarbital 
produced the most intense impairment. 
Chlorpromazine produced an impairment 
of function after a delay of several hours. 
Meprobamate also produced delayed im-
pairment after the first dose and prompt 
impairment after the second dose. 
Zirkle and colleagues337 have shown that 
400 mg. of meprobamate four times daily 
for 1 week in normal subjects had an in-
creased depressant effect on coordination 
and judgment when combined with 95 per 
cent ethyl alcohol in sufficient quantity to 
produce an estimated 0.05 per cent blood 
alcohol level. These investigators found 
that meprobamate alone, alcohol alone, and 
meprobamate plus alcohol, in that order, 
increasingly impaired performance signifi-
cantly from that of a placebo. There was 
no significant difference in the blood alco-
hol levels of alcohol treatment alone or 
with meprobamate, indicating that me-
probamate did not enhance the absorption 
or interfere with the metabolism of alcohol. 
The results indicated a definite additive 
and possibly a potentiating effect of mepro-
bamate on alcohol. If the placebo percent-
age of success was counted as 100, the 
comparative percentages of success in the 
drug states were: meprobamate, 95; al-
cohol, 90; and meprobamate-alcohol, 80. 
The expected deficit for the combination of 
drugs would have been 85 per cent. Inas-
much as 80 per cent successful perform-
ance was obtained, a true mild potentiating 
effect of meprobamate may have been ob-
served. A study by Kopmann and Hughes182 
using rats would support the above human 
data. The latter investigators studied the 
effects of various central nervous system 
depressants alone and in combination with 
ethyl alcohol on anxiety, discrimination, 
and extinction of a learned response in-
volVing two choice discriminations in a 
three chamber shock avoidance box. Me-
probamate, phenaglycodol, and alcohol de-
creased anxiety, discrimination, and the 
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ability to respond. As expected, chlorprom-
azine in doses which were ineffective alone 
markedly potentiated the depressant effects 
of alcohol. Unexpectedly, the authors found 
that meprobamate as well as phenaglycodol 
and pentobarbital potentiated the depres-
sion of behavior induced by ethyl alcohol. 
The depressant effects of reserpine were 
merely additive to those of ethyl alcohol. 
These findings merit further study. Tenta-
tively, the evidence suggests that mepro-
bamate and alcohol may not merely show 
additive depressant properties but true 
potentiation. It is of interest that Joyce and 
colleagues"lO have obtained evidence that 
a similar potentiation rather than simple 
addition is present in nonnal subjects who 
ingested phenobarbital and ethyl alcohol. 
The effects of various central nervous 
system depressants on the disruptive effects 
of anxiety on performance of a perceptual 
motor task (keeping a pointer on a target) 
have been studied by Holliday and Dille." 39 
Anxiety was produced by random "punish-
ment" for being off target. The punishment 
consisted of a slight electric shock, a blast 
of air on the neck, or a hom blast. The 
drugs tested included meprobamate (800 
mg.), pentobarbital (100 mg.), chlorprom-
azine (50 mg.), and a placebo given to 
patients on a double blind basis. Of the 
drugs tested, only meprobamate tended to 
abolish the disruptive effects of anxiety on 
learning as measured in this study. 
In order to help answer the question of 
whether pilots of airplanes should be al-
lowed to fly while under the influence of 
various tranquilizers, McGuire and Leary209 
studied the effects of a placebo, promazine 
(50 mg.), and meprobamate (400 mg.) 
given four times daily on stress tolerance. 
Various tests of circulatory "overshoot" or 
compensation to the Valsalva maneuver, 
continuous positive pressure breathing, the 
tilt table, and exercise tolerance were used. 
As might be expected of adrenergic block-
ing agents, promazine caused a reduction 
of stress tolerance. However, meprobamate 
also depressed stress tolerance. As the de-
gree of stress increased, the limitation of 
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response became severe with both groups 
of tranquiliZing agents. Large doses of 
both active pharmacologic agents caused 
even more severe limitations of circulatory 
compensation. 
An investigation by Lienert and Traxepo3 
showed the galvanic skin response to emo-
tion-laden statements to subjects given 
meprobamate or alcohol was significantly 
reduced. These drug effects were more 
marked with highly emotional subjects. 
Uhr and Miller312 studied the effects of 
single doses of emylcamate (400 to 800 
mg. ), meprobamate (800 mg. ), and match-
ing placebos on various psychologic tests 
examining stress reactions in normal male 
volunteers. No drug effects were found on 
performance under either physical stress 
or threat of stress situations. Meprobamate 
had a consistent effect in raising galvanic 
skin resistance, which is consistent with 
the findings of Laties196 that meprobamate 
decreases palmar sweating, but it is not 
consistent with a previous study of Marquis 
and colleagues217 that determined mepro-
bamate increases sweating. Both mepro-
bamate and emylcamate led to feelings of 
less activity, the latter being more potent. 
Jonsson and Andersen158 studied the ef-
fects of emylcamate, meprobamate, and a 
placebo given on a double blind basis to 
psychiatric patients ready for discharge 
from a hospital. A battery of psychologic 
tests which included sixteen variables was 
used. Meprobamate in single doses of 1,200 
and 1,800 mg. significantly impaired per-
formance on the vigilance test, various vis-
ual-motor dexterity tests, and grip strength. 
Single doses of 1,200 mg. of emylcamate 
caused no impairment of performance, 
while 1,800 mg. had a depressant effect 
similar to meprobamate. Both drugs, even 
in doses of 1,800 mg., had no effect on the 
flicker fusion test. 
Actions on the human electroencephal-
ogram. In man, oral doses of 1,600 and 
2,000 mg. of meprobamate produce bar-
biturate-like fast waves of 20 to 30 cycles 
per second in the cortical electroencephalo-
gram, especially in the parietal areas. 248 
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Such electroencephalographic fast wave 
activity also has been observed by others.279 
Bokonjic and Trojaborg35 have studied 
the effect of a wide range of doses of me-
probamate (15 to 400 mg. per kilogram, 
orally) on the electroencephalogram of 
patients during treatment, during intoxica-
tion, and after abrupt withdrawal. In cer-
tain respects, meprobamate and the bar-
biturates have similar effects on the elec-
troencephalogram. Both drugs induce fast 
wave activity which is more pronounced 
during drowsiness and disappears during 
sleep. Both drugs show evidence of toler-
ance to these electroencephalographic 
changes. After abrupt withdrawal of both 
agents, paroxysmal electroencephalographic 
changes are noted during photic stimula-
tion. In confirmation of the work of Pfeiffer 
and colleagues, the cortical distribution of 
the fast frequency activity seems to differ. 
After meprobamate, the electroencephalo-
graphic fast wave activity tends to be most 
pronounced in the parietal areas, while 
after barbiturates, it is most pronounced 
frontally, frontotemporally, or parietally. 
After withdrawal of meprobamate, the 
paroxysmal electroencephalographic 
changes rarely persist as long as 2 weeks. 
After withdrawal of barbiturates, the 
changes may last 2 months. The principal 
differences between the electroencephalo-
graphic effects of meprobamate and barbi-
turates occur after ingestion of toxic doses. 
After meprobamate poisoning, the fast 
waves persist even during the period of 
unconsciousness. Frequencies of less than 
6 cycles per second rarely are seen. The 
electroencephalogram usually is normal 48 
hours after doses as large as 400 mg. per 
kilogram orally. The electroencephalo-
graphic fast wave activity persists only with 
small doses of barbiturates. After large toxic 
doses, the fast wave activity is replaced by 
2 to 6 cycles per second activity of high 
amplitude. It may take weeks for the elec-
troencephalogram to become normal, al-
though admittedly this could be secondary 
to brain damage caused by hypoxia result-
ing from severe respiratory depression. 
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Metabolic fate. The metabolic fate of 
meprobamate was investigated initially in 
animals and man by Berger27 and Agranoff, 
Bradley, and Axelrod. 3 Subsequently, Wal-
ken stein and colleagues320 extended these 
studies. When meprobamate is adminis-
tered orally to dogs, it is readily absorbed 
into the blood stream. Peak blood concen-
trations are observed 1 to 2 hours after ad-
ministration. The levels then decline for 10 
or more hours. Significant amounts appear 
in the urine within 30 minutes after an oral 
dose, and most of the meprobamate is ex-
creted within 24 hours, especially in rats 
and dogs. Feces contain less than 10 per 
cent of the dose. Approximately 50 per 
cent of the amount present in blood is un-
changed meprobamate. After administra-
tion to rats, the lungs, kidney, and liver 
show the greatest drug concentration. The 
major metabolite, accounting for 60 per cent 
of the administered dose to dogs, is hy-
droxymeprobamate, which does not exhibit 
meprobamate-like activity. About 10 to 12 
per cent of the meprobamate in urine is un-
changed; the rest are metabolites conju-
gated with glucuronic acid. Agranoff, 
Bradley, and Axelrod showed that follow-
ing single doses of 1,600 mg. of mepro-
bamate orally to 4 human subjects, the 
drug is excreted relatively slowly for at 
least 48 hours after administration. About 
12 to 20 per cent of the administered me-
probamate was excreted unchanged in the 
urine. Walkenstein and colleagues obtained 
similar findings in 9 human subjects given 
1 Gm. of meprobamate as a single oral 
dose. About 0.66 per cent of the mepro-
bamate given was excreted unchanged in 
the first 2 hours. The excretion rate then 
doubled during the next 2 hours and re-
mained at this level to the twelfth hour. 
By this time, about 7 per cent of the drug 
was excreted unchanged. A gradual de-
crease was observed in the excretion rate 
from 24 to 48 hours, which accounted for 
only 1l.5 per cent unchanged meprobamate 
over the 48 hour period. Recently, Ludwig 
and associates"07 have reported that 2-
hydroxymethyl-2-propyl-1,3-propanediol di-
Tranquilizing drugs 647 
carbamate is not the major unconjugated 
metabolite of meprobamate, as reported 
previously by others. These investigators 
have established the metabolite to be 2-
methyl-2( ,B-hydroxypropyl )-1, 3-propane-
diol dicarbamate. Compared to mepro-
bamate this agent is pharmacologically 
impotent. Emmerson, Miya, and Yim91 
studied the distribution of C14-labeled me-
probamate in the rat after intraperitoneal 
administration. The distribution of mepro-
bamate was similar in the cerebrum, cere-
bellum, midbrain, and hindbrain (a section 
just at the anterior border of the pons to 
one below the medulla). In nephrecto-
mized rats, three compounds, a glucuro-
nide, hydroxymeprobamate, and meproba-
mate, were found in the blood, but only 
meprobamate was present in the brain. 
Phillips, Miya, and Yim249 administered 
meprobamate to rats for a period of 35 
days. Definite tolerance was shown to de-
velop, as evidenced by a decrease in motor 
activity within 1 hour after meprobamate 
administration. Blood and brain levels of 
C14-labeled meprobamate in the carbamate 
positions were approximately the same 
within 1 hour after drug administration. 
Subsequently, the level of meprobamate 
in the tolerant animals decreased much 
more rapidly than in nontolerant animals. 
A marked increase in urinary excretion of 
the glucuronide metabolites of meproba-
mate was observed in the tolerant animals. 
It would appear that the tolerance to me-
probamate indicated by a decrease in motor 
activity within 1 hour was due to cellular 
adaptation of the nervous system, while 
the enhanced metabolism of the drug was 
responsible for a marked shortening of its 
duration of action. Other investigators have 
shown that tolerance to the barbiturates 
may also involve an increased rate of me-
tabolism of the active compound to phar-
macologically inactive metabolites. 65 Cross 
tolerance of meprobamate with other phar-
macologic agents has been demonstrated 
presumably by increasing the activity of 
the enzyme systems responsible for the 
metabolism of meprobamate. 04, 1M, 1"5 
648 Domino 
Physical dependence. It is now well 
known that meprobamate may produce 
physical dependence in animals and man 
if taken in sufficient dosage. Swinyard, 
Chin, and Fingl'00 studied the effects of 
chronic oral administration of meproba-
mate to albino mice using the threshold to 
low frequency electroshock as an index of 
central nervous system excitability. After 
several days of treatment, marked toler-
ance developed to the usual seizure thresh-
old~elevating effect of meprobamate. After 
12 to 16 days of chronic meprobamate ad-
ministration, the seizure thresholds were 
below normal, indicating withdrawal hy-
perexcitability. Withdrawal hyperexcita-
bility was detectable 4 and 8 hours after 
drug withdrawal and subsided within 28 
hours. This was in marked contrast to with-
drawal caused by chronic ethanol or phe-
nobarbital administration. With the latter 
agents, there is little hyperexcitability in 
mice for the first 24 hours, but it is maxi-
mal on the second or third day and de-
clines progressively over the next 4 days.21l 
In dogs, gross signs of withdrawal from 
chronic meprobamate administration twice 
daily occurred 12 to 16 hours after the last 
dose. Grand mal seizures occurred about 
24 hours after withdrawal, with three of 
four animals dying after several seizures. 93 
A previous study by Fraser and Isbell in 
dogs chronically administered various bar-
biturates also showed these agents pro-
duced an abstinence syndrome. Secobar-
bital, amobarbital, pentobarbital, and bar-
bital were given once daily, except for one 
group given pentobarbital five times a day. 
Secobarbital and amobarbital produced 
mild or inconsistent signs of abstinence, 
probably caused by the fact that com-
pounds are short acting and were given 
only once a day. The animals given pento-
barbital in divided daily doses showed 
more marked withdrawal symptoms, in-
cluding grand mal convulsions, while bar-
bital produced the most marked abstinence 
syndrome, with convulsions within 21 to 
48 hours. During the first few weeks of in-
toxication, all animals showed evidence of 
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tolerance development to the sedative ef-
fects. Superficially, it would appear that in 
dogs, withdrawal to the shorter-acting bar-
biturates is less severe than in man,156 but 
this is probably related to the lack of main-
taining persistent 24 hour blood levels of 
these agents in the dog. 
Bulla, Ewing, and Buffaloe"" extended 
the previous study of Haizlip and Ewing124 
in patients using smaller doses of mepro-
bamate over a longer period of time. In a 
controlled study using psychotic patients, 
it was shown that 2,400 mg. or less of me-
probamate per day did not lead to with-
drawal symptoms in the majority of pa-
tients. These findings confirm those of Boyd 
and colleagues38 who failed to show with-
drawal symptoms following similar doses 
of meprobamate given to more elderly 
patients. On the other hand, that doses 
of 3.2 and 6.4 Gm. of meprobamate and 
more per day given chronically led to defi-
nite physical dependence and withdrawal 
symptoms was shown by Haizlip and Ew-
ing." 24 These investigators conducted a 
double blind study with three identical 
groups of male psychiatric inpatients who 
were given placebo or meprobamate at 
two dose levels (3.2 and 6.4 Gm. per day). 
Marked sedative effects were observed with 
meprobamate for the first few days. Of 47 
patients, 35 showed a staggering gait or in-
ability to stand or walk without falling. 
These effects gradually diminished over the 
next 7 to 10 days, indicating tolerance de-
velopment. At the end of 40 days of daily 
treatment, all patients were switched to a 
placebo. A total of 44 of 47 patients showed 
objective evidence of withdrawal. The typ-
ical syndrome of meprobamate withdrawal 
consisted of insomnia, vomiting, tremors, 
muscle twitching, anxiety, anorexia, and 
ataxia. Eight patients had hallucinations, 
anxiety, and tremors resembling delirium 
tremens between 36 and 48 hours after 
withdrawal of meprobamate. Three of the 
patients developed grand mal seizures 
within this same period of time after drug 
withdrawal. The results obtained were sta-
tistically significant. Hollister and Glaz-
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ener144 showed that only 10 of 60 patients 
switched from usual therapeutic doses of 
meprobamate to placebo had a recrudes-
cence of symptoms. A definite withdrawal 
syndrome was observed in 16 of 21 pa-
tients with mean daily doses of 5.8 Gm. A 
similar picture was observed following ab-
rupt withdrawal of equally large doses of 
meprobamate combined with promazine 
(600 to 800 mg. daily). The plasma levels 
of high doses of meprobamate daily in 23 
patients after withdrawal indicated a half-
life of meprobamate of approximately 24 
hours. 
Untoward effects and toxicity. Consider-
ing its widespread use, meprobamate in 
usual therapeutic doses produces relatively 
few adverse effects. Serious effects such as 
thrombocytopenic purpura, leukopenia, 
and aplastic anemia have been reported, 
but these are rare. Allergic symptoms have 
been observed. These usually occur after 
a few doses of the drug. The incidence of 
reactions is not apparently related to a 
previous history of allergy. The mild reac-
tions consist of an urticarial or erythema-
tous maculopapular rash which may be 
confined to the groin or generalized. Acute 
non thrombocytopenic purpura with fever 
and edema has also been seen. Serious re-
actions including marked fever, fainting 
spells, angioneurotic edema, and bronchial 
spasm may also occur. 
Ingestion of large amounts of mepro-
bamate, particularly in cases of overdosage 
with suicidal intent, may result in coma, 
cardiovascular shock, and respiratory col-
lapse and death. Cann and -Verhulst ana-
lyzed the case reports of 93 patients with 
meprobamate overdosage. In this series, 
there were no deaths, although deaths have 
been reported by others. Drowsiness, leth-
argy, stupor, and coma in adults occurred 
in doses of 4 to 9.6 Gm., with 1 patient 
ingesting 19.2 Gm. Accidental overdosage 
of meprobamate in children does occur, 
but not as much as might be expected, in 
part perhaps as a result of the bitter taste 
of the drug. The clinical picture of over-
dosage in children resembles that in man. 
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It would appear that suicide attempts with 
meprobamate are not too successful (eight 
in the literature to 1961) because of the 
large quantities of the drug necessary to 
produce coma and death. Deaths have fol-
lowed ingestion of as little as 12 and 20 
Gm., but doses up to 40 Gm. have been 
taken by some patients with recoveryYl 
Kamin and Shaskan163 reported a patient 
who ingested 47.6 Gm. and died of aspira-
tion and pulmonary congestion. 
Chlordiazepoxide 
Chlordiazepoxide is a member of a new 
class of chemicals of unusual structure. The 
compound is 7 -chloro-2-methylamino-5-
phenyl-3H -1,4-benzodiazepine-4-oxide hy-
drochloride, as shown below: 
O 
~HCH, 
~ -N=C 
I ;CH,.HCI 
/~ -C=N 
a () '0 
It was syntheSized by Sternbach and 
Reeder. The colorless crystalline material 
is highly soluble in water. It is unstable in 
solution, and the powder must be pro-
tected from light. 
Randall and colleagues262 described this 
agent as having sedative, anticonvulsant, 
and skeletal muscle relaxant properties but 
weak hypnotic effects in animals. It pro-
duces taming of vicious animals and an 
appetite-stimulating effect in rats and dogs. 
These investigators described chlordiaze-
poxide as qualitatively similar to mepro-
bamate as a tranquilizer but more potent. 
Liberson202 has pOinted out that the be-
havioral effects of chlordiazepoxide in 
hungry, nxated rats appears to be different 
from those of other drugs used as tran-
quilizers in man. For example, chlorproma-
zine tends to suppress the avoidance of 
the grid shock. Meprobamate tends to de-
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lay the reactions of the rat and slow the 
rate of learning. In confirmation of Feld-
man's results, chlordiazepoxide tends to 
prevent fixations in rats. In contrast to the 
other tranquilizers, the drug does not sup-
press avoidance to grid shock and short-
ens the reaction times even more than psy-
chic energizers. The role of the appetite-
stimulating effect of chlordiazepoxide in 
rats in these behavioral changes was not 
determined. No data are as yet available 
as to whether the psychopharmacologic ef-
fects of chlordiazepoxide in rats apply to 
humans. 
Sedative effects. In man, chlordiazepox-
ide has mild sedative effects which parallel 
the effects observed in animals. 302 Rela-
tively few clinical reports have appeared 
in which double blind techniques or ac-
curate comparisons to standard sedatives 
have been made. Scherbel272 studied the 
action of chlordiazepoxide and a placebo 
in various diseases. Usually, 10 mg. three 
times daily was given to patients with a 
variety of organic and functional disorders. 
He concluded the compound is effective 
in relieving anxiety and its accompanying 
somatic reactions. The adverse effects in-
cluded increased drowsiness and need for 
sleep, increased appetite, ataxia, muscle in-
coordination and weakness, decreased lib-
ido, decreased tolerance to alcohol, and in 
some patients, aggravation of a depressive 
reaction. Elderly patients were found to 
be very sensitive to even small doses. In 
addition, a cumulative effect was observed 
in some patients. This is in accord with 
Hollister, Motzenbecker, and Degan's145 
observations that the plasma levels of the 
drug indicate a half-life of approximately 
48 hours following very large daily doses 
( 300 to 600 mg. ). These are about 10 times 
the usual therapeutic dose. 
Anticonvulsant effects. Contrary to the 
reports of Kaim and Rosenstein and of 
Rosenstein'02 that chlordiazepoxide is an 
anticonvulsant in man, Livingston, Pauli, 
and Murphy204 found it ineffective in 
doses of 70 to 125 mg. per day in resistant 
epileptics who also failed to respond to 
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standard anticonvulsant drugs. Some im-
provement in behavior was noted in a few 
patients with hyperkinetic manifestations. 
In addition, these latter investigators found 
the agent produced numerous untoward 
effects, including anorexia, drowsiness, ag-
gressive destructive behavior, ataxia, and 
a decrease in potency. 
Metabolic fate. Unfortunately, relatively 
few data are available on the blood levels 
and metabolites of chlordiazepoxide. It ap-
pears in the blood a few minutes after oral 
administration, and peak levels are attained 
about 2 hours later. 335 Both in rats and 
man, C14-labeled chlordiazepoxide was rap-
idly absorbed from the intestine.178 
Part of the drug was secreted into the 
stomach and reabsorbed, while part was 
excreted into the feces. These effects per-
sisted for about 48 hours in the rat but 
longer in man. The agent was extensively 
metabolized in both species. None of the 
C14-labeled material appeared as C 140" in 
the lungs. Rats excreted predominantly 
basic while humans excreted acidic metab-
olites. Hollister, Motzenbecker, and De-
gan145 have estimated on the basis of 
plasma levels following abrupt withdrawal 
of very large daily doses (300 to 600 mg. ) 
to psychiatric patients that chlordiazepox-
ide has a plasma half-life of apprOXimately 
48 hours. 
Physical dependence. To date, there is 
no evidence that the chronic ingestion of 
usual therapeutic doses of chlordiazepoxide 
leads to physical dependence. It is of in-
terest that the drug can relieve the symp-
toms of delirium tremens or alcohol with-
drawal. It is pertinent, therefore, to ask if 
the drug can substitute for alcohol or act 
through some other unknown mechanism 
as do the substituted phenothiazines. That 
chlordiazepoxide in enormous dosage is 
capable of producing physical dependence 
and withdrawal symptoms is evident from 
a study by Hollister, Motzenbecker, and 
Degan.145 These investigators studied the 
effects of large doses (100 to 600 mg.) of 
chlordiazepoxide given daily for 1 to 7 
months to 36 hospitalized psychiatric pa-
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tients. Some clinical improvement was 
noted in 9 patients. Dizziness, weakness, 
unsteadiness, and sleepiness were noted 
usually after rapid increments of dosage 
from an initial dose of 25 mg. three times 
a day. Some patients were agitated after 
chlordiazepoxide and required a reduction 
in dosage. Ten of the 11 patients who re-
ceived 300 to 600 mg. of chlordiazepoxide 
daily for several months showed new symp-
toms and signs of drug withdrawal when 
switched abruptly to placebos. Depression, 
agitation, insomnia, loss of appetite, nausea, 
aggravation of the psychosis, and grand 
mal seizures were noted 2 to 8 days after 
drug withdrawal. Minor electroencephalo-
graphic abnormalities (primarily slowing) 
were produced by chronic administration 
of large doses. The prolonged plasma half-
life of this agent (48 hours after abrupt 
withdrawal) correlates with the relative 
slow onset of withdrawal symptoms. 
Untoward effects and toxicity. Zbinden 
and colleagues335 summarized the experi-
mental and clinical toxicology of chlordiaz-
epoxide. In most of the 22 patients who 
took the drug with suicidal intent, single 
doses up to 2,250 mg. caused sedation, 
ataxia, and dysarthria. In a few instances, 
sleep and coma were noted. One healthy 
male volunteer ingested 50 mg. on the first 
day, 150 mg. on the second day, 500 mg. 
on the third day, and 1,000 mg. daily for 
another 9 days. The subject exhibited eu-
phoria, loss of equilibrium, and difficulty 
concentrating after the third day. Follow-
ing the very large doses (500 to 1,000 mg. 
per day), the subject was euphoric most of 
the time; later, he was hostile and irritable. 
N ear the end of the experiment, he was 
ataxic and dysarthric. The symptoms disap-
peared progressively over about 5 days 
after cessation of medication. No signs of 
withdrawal were noted. 
It has been repeatedly observed in many 
of the patients who attempted suicide with 
chlordiazepoxide that although they fell 
asleep, they could easily be aroused and 
were able to talk, eat, and drink. In the ani-
mal studies as well, the induced sleep was 
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not deep. Single or repeated doses of chlor-
diazepoxide did not markedly affect arte-
rial blood pressure, response to epineph-
rine or serotonin, or respiration. In a case 
of attempted suicide, marked vagotonia 
was noted which ceased after adminis-
tration of atropine. Zbinden and colleagues 
were able to show in mice a synergistic 
effect between chlordiazepoxide and phe-
nobarbital. The hypnotiC effects of chloral 
hydrate, methyprylon, glutethimide, and 
ethyl alcohol were moderately or slightly 
enhanced. Clinically, there are few data 
available on the effects of such combina-
tions. Of 22 patients who attempted to 
commit suicide, only 4 patients who took 
chlordiazepoxide in addition to high doses 
of methyprylon, imipramine, ethchlorvynol, 
and promazine plus alcohol did not show 
excessive sedation or coma. Obviously, 
much more data are necessary to determine 
whether the effects in animals or man are 
merely additive, synergistic, or due to true 
potentiation. In animal experiments, vari-
ous analeptic agents were effective in coun-
teracting the depressant effects of chlor-
diazepoxide. These included megimide, 
pentylenetetrazol, DL-amphetamine, and 
caffeine. Of considerable clinical impor-
tance is the observation that gastric lavage 
did not apparently markedly change the 
clinical picture of chlordiazepoxide intoxi-
cation because the drug appears in the 
blood within a few minutes, and peak 
levels occur in 2 hours after oral ingestion. 
Nevertheless, it would appear to be good 
clinical practice to perform gastric lavage 
as soon as possible even though much of 
the drug may already be absorbed. 
Lemere201 reported that 4 patients given 
doses of chlordiazepoxide in excess of 80 
mg. per day had behavioral intoxication 
with cumulative effect as suggested by the 
gradual onset of intoxication and the pro-
longed period (3 to 5 days) required for 
recovery following cessation of medication. 
Miller224 has emphasized the importance 
of behavioral toxicity as a side reaction to 
chlordiazepoxide and other psychoactive 
drugs. In a double blind study using 20 
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mg. of chlordiazepoxide and matching 
placebos given daily for 1 week to normal 
male subjects, significant interference with 
judgment and vision in a simulated driving 
test were noted with the active drug. 
Whitelaw"2" reported that chlordiaze-
poxide produced menstrual irregularities in 
12 of 17 female infertility patients with 
previously normal cycles. A delay or failure 
to ovulate with premature or delayed men-
struation was noted. The author suggested 
that this effect was similar to other tran-
quilizing agents. 
One possible untoward effect of chlor-
diazepoxide which merits further attention 
is its role in causing agranulocytosis. Liv-
ingston, Pauli, and Murphy204 reported that 
1 patient on trimethadione and chlordiaz-
epoxide developed fulminating agranulo-
cytosis that resulted in death. Chlordiaz-
epoxide alone also may produce agranu-
locytosis,161 however the patient observed 
recovered upon withdrawal of the drug. 
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